--------------------------------------------------------------------------------

LICENSE AGREEMENT
BETWEEN
PALOMAR MEDICAL TECHNOLOGIES, INC.
AND THE PROCTER & GAMBLE COMPANY
AND
THE GILLETTE COMPANY

--------------------------------------------------------------------------------

Table of Contents

1 License Grant and Right of Reference 1 1.1     License Under LICENSED PATENTS
and LICENSED KNOW-HOW 1 1.2     License and Right of Reference Under PALOMAR
REGULATORY DOCUMENTATION 1 1.3     P&G’s Right to Sublicense 2 1.4     Other
Project Technology Licenses 2 1.5    PALOMAR’s Right to Sublicense 3 1.6  
 License Limitations 3 1.7    No Other Licenses Granted 4 1.8    ** 4 2
Development, Regulatory and Commercialization Matters 4 2.1    Development 4
2.2    Regulatory Activities and Approvals 4 2.3    Commercialization 5 2.4  
 TRADEMARKS 6 3 Payments & Reports 6 ** 3.2     NOS-Based Payments 6 3.3     TTP
Payments 6 3.4     Royalty Payments 7 3.5    Combination Products 8 3.6    THIRD
PARTY Royalties 8 3.7    THIRD PARTY Royalties Owed by PALOMAR 9 3.8   TTP and
Royalty Payments 9 3.9    TTP and Royalty Statements 10 3.10   Records
Retention; Audit 10 3.11   Mode of Payment 11 3.12   Interest on Late Payments
11 3.13   Withholding 11 3.14   Blocked Payments 11 ** 4 Intellectual Property
11 ** 4.3    Prosecution of PATENTS 12 4.4    Enforcement of PATENTS 12 4.5  
 PATENT Marking 12 5 Confidentiality and Nondisclosure 12 5.1    Confidentiality
Obligations 12 ** 5.3    CONFIDENTIAL INFORMATION 15 5.4    Public Domain 16 5.5
    Use of Name 16 5.6     Press Releases and SEC Filings 17 5.7     Return of
CONFIDENTIAL INFORMATION 17 ** ** This material was omitted pursuant to a
request for confidential treatment and was separately filed with the SEC on
March 3, 2008.

ii

--------------------------------------------------------------------------------

6 Termination of ORIGINAL AGREEMENT 18 6.1     Termination of ORIGINAL AGREEMENT
18 6.2     Effects of Termination of ORIGINAL AGREEMENT 18 7 Term and
Termination of this AGREEMENT 18 7.1    Term 18 7.2    Rights of Termination 18
7.3     Effect of Termination 19 7.4     Notice of Certain Sublicense Grants 20
7.5     Accrued Rights; Rights Cumulative; Surviving Obligations 20 7.6   
 Rights in Bankruptcy 21 8 ** 8.4     Limitation on Damages and Liability 21 8.5
     Insurance 22 9 ** 10 Dispute Resolution 23 10.1      In General 23 10.2   
 Internal Escalation 23 10.3     DISPUTES 23 10.4     DISPUTES Regarding
Inventorship of PROJECT INVENTIONS 24 10.5     Tolling 26 10.6      Interim
Relief 26 11 Miscellaneous 26 11.1     Force Majeure 26 11.2    Assignment;
Change of Control 26 11.3    Severability 27 11.4     Governing Law 27 11.5    
Notices 27 11.6     Export Control 29 11.7     Entire AGREEMENT; Modifications
29 11.8      Relationship of the PARTIES 29 11.9      Waiver 29 11.10   
Counterparts 29 11.11   No Benefit to THIRD PARTIES 30 11.12   Further Assurance
30 11.13   Transaction Costs 30 11.14   References 30 11.15    Construction 30
Exhibits Exhibit A -- Definitions Exhibit B -- Letter of Authorization Exhibit C
-- FIRST PRESS RELEASE Exhibit D -- LICENSED PATENTS       ** This material was
omitted pursuant to a request for confidential treatment and was separately
filed with the SEC on March 3, 2008.

iii

--------------------------------------------------------------------------------

Schedules Schedule 2.2.2 -- ** Schedule 4.2.2 -- ** ** Schedule A-68 -- MGH
PATENTS       ** This material was omitted pursuant to a request for
confidential treatment and was separately filed with the SEC on March 3, 2008.

iv

--------------------------------------------------------------------------------

Preamble

        This agreement (“AGREEMENT”), entered into as of the last date of
execution of this AGREEMENT (“EXECUTION DATE”), and retroactively effective as
of February 14, 2003 (“EFFECTIVE DATE”), is between Palomar Medical
Technologies, Inc., a Delaware corporation (“PALOMAR MEDICAL TECHNOLOGIES,
INC.,” and collectively with its AFFILIATES, “PALOMAR”), on the one hand, and
The Procter & Gamble Company, an Ohio corporation (“The PROCTER & GAMBLE
COMPANY,” and collectively with its AFFILIATES, “P&G”) and its wholly-owned
subsidiary, The Gillette Company (“GILLETTE”), on the other hand.

        PALOMAR owns or otherwise controls certain patents and know-how relating
to light-based products and systems for, among other things, the management and
removal of human hair.

        PALOMAR and GILLETTE previously entered into that certain Amended and
Restated Development and License Agreement dated as of February 14, 2007, and
effective as of February 14, 2003, as further amended as of February 14, 2007
and December 21, 2007 (collectively, the “ORIGINAL AGREEMENT”), and PALOMAR and
GILLETTE are terminating and superseding such ORIGINAL AGREEMENT pursuant to the
terms and conditions of this AGREEMENT.

        PALOMAR and P&G now desire to enter into this AGREEMENT, through which
P&G will obtain a non-exclusive license under certain of PALOMAR’s patents and
know-how pursuant to the terms and conditions set forth in this AGREEMENT.

        The PARTIES therefore agree as follows:

1.

License Grants and Right of Reference

1.1.  

License Under LICENSED PATENTS and LICENSED KNOW-HOW. PALOMAR hereby grants P&G
a worldwide, non-exclusive, royalty-bearing license (with the right to
sublicense only as permitted in Section 1.3) under PALOMAR’s rights, titles, and
interests in and to the LICENSED PATENTS and LICENSED KNOW-HOW to EXPLOIT
LICENSED PRODUCTS only, and only in the FEMALE FIELD.

1.2.  

License and Right of Reference Under PALOMAR REGULATORY DOCUMENTATION.

1.2.1.  

License and Right of Reference. PALOMAR hereby grants P&G a worldwide,
non-exclusive, royalty-bearing license and right of reference (with the right to
sublicense only as permitted in Section 1.3), under the PALOMAR REGULATORY
DOCUMENTATION, to EXPLOIT LICENSED PRODUCTS only, and only in the FEMALE FIELD.

1.2.2.  

Letter of Authorization. No later than the EXECUTION DATE, PALOMAR shall provide
to P&G a letter of authorization that grants to P&G a right of access and
reference with respect to specified PALOMAR REGULATORY DOCUMENTATION for use
only with LICENSED PRODUCTS in the FEMALE FIELD consistent with Section 1.2.1,
which letter shall be in the form attached hereto as Exhibit B and shall be
irrevocable except in the event of termination of this AGREEMENT by PALOMAR
pursuant to Section 7.2.1 or 7.2.3, or by P&G pursuant to Section 7.2.2, in
which case such letter shall automatically be revoked and P&G and its
sublicensees shall no longer use, refer to or rely on such letter in any way.

1

--------------------------------------------------------------------------------

1.3.  

P&G’s Right to Sublicense. The licenses in Section 1.1 and Section 1.2 include
the right for P&G to sublicense THIRD PARTIES only as may be reasonably
necessary for: (a) the manufacture of LICENSED PRODUCTS on behalf of P&G or any
of its permitted sublicensees for resale to P&G or any of its permitted
sublicensees, (b) THIRD PARTY distributors to sell or otherwise distribute
LICENSED PRODUCTS manufactured by or on behalf P&G for use in the FEMALE FIELD,
(c) the importation, sale, offering for sale, transport, distribution,
promotion, manufacturing and marketing of LICENSED PRODUCTS in the FEMALE FIELD
in markets other than any MAJOR MARKET, (d) the limited purpose of
(sub)contracting activities that P&G would have a right to perform directly
hereunder, subject to provisions safeguarding non-disclosure and non-use at
least as strict as those provided in this AGREEMENT, or e) in connection with
P&G’s entering into a THIRD PARTY COLLABORATION. In the event of the termination
of the license grants in Section 1.1 and Section 1.2 for any reason, PALOMAR
shall have the right to terminate any such sublicense. P&G shall be responsible
to PALOMAR for the performance of any of P&G’s permitted sublicensees under any
provisions of this AGREEMENT for which P&G is responsible. P&G shall not permit
any sublicensees to use or disclose any LICENSED KNOW-HOW or PALOMAR REGULATORY
DOCUMENTATION (to the extent such documentation constitutes PALOMAR CONFIDENTIAL
INFORMATION) without provisions safeguarding non-disclosure and non-use at least
as strict as those provided in this AGREEMENT (including the rights to use and
disclose same as provided in Article 5). Apart from the foregoing limited rights
to sublicense, P&G shall not have any right to grant to any THIRD PARTY any
sublicense under the licenses granted to P&G in Section 1.1 and Section 1.2 or
to assign those licenses or the license granted to P&G in Section 1.4.1, without
PALOMAR’s prior written consent, provided that P&G may assign such licenses in
connection with the permitted assignment of this AGREEMENT in full pursuant to
Section 11.2.

1.4.  

Other Project Technology Licenses.

1.4.1.  

License Under PALOMAR PROJECT TECHNOLOGY & JOINT PROJECT TECHNOLOGY –
NON-LIGHT-BASED PRODUCT. PALOMAR hereby grants P&G a worldwide, exclusive
(including with regard to PALOMAR), perpetual and irrevocable, royalty free
license, under PALOMAR’S rights, titles, and interests in and to the PALOMAR
PROJECT TECHNOLOGY **, and the JOINT PROJECT TECHNOLOGY **, to EXPLOIT
NON-LIGHT-BASED PRODUCTS only. The license in this Section 1.4.1 includes the
right for P&G to sublicense THIRD PARTIES through multiple tiers of
sublicensing.

**  

This material was omitted pursuant to a request for confidential treatment and
was separately filed with the SEC on March 3, 2008.

2

--------------------------------------------------------------------------------

1.4.2.  

P&G PROJECT TECHNOLOGY & JOINT PROJECT TECHNOLOGY -- LIGHT-BASED DEVICES Outside
FIELD. P&G hereby grants PALOMAR a worldwide, exclusive (including with regard
to P&G), perpetual and irrevocable, royalty free license, under P&G’s rights,
titles, and interests in and to the P&G PROJECT TECHNOLOGY **, and the JOINT
PROJECT TECHNOLOGY **, to EXPLOIT LIGHT-BASED DEVICES only, and only outside of
the FIELD. The license in this Section 1.4.2 includes the right for PALOMAR to
sublicense THIRD PARTIES through multiple tiers of sublicensing.

1.4.3.  

P&G PROJECT KNOW-HOW -- LIGHT-BASED DEVICES In FIELD. P&G hereby grants PALOMAR
a worldwide, non-exclusive, royalty-free license, under P&G’s rights, titles,
and interests in and to the P&G PROJECT KNOW-HOW (including P&G PROJECT
INVENTIONS to the extent not covered or claimed by any P&G PROJECT PATENT) ** to
EXPLOIT LIGHT-BASED DEVICES only, and only in the FIELD.

1.5.  

PALOMAR's Right to Sublicense. The license in Section 1.4.3 includes the right
for PALOMAR to sublicense THIRD PARTIES only as may be reasonably necessary for:
(a) the manufacture of LIGHT-BASED DEVICES on behalf of PALOMAR or any of its
permitted sublicensees for resale to them, (b) THIRD PARTY distributors to sell
or otherwise distribute LIGHT-BASED DEVICES manufactured by or on behalf PALOMAR
or any of its permitted sublicensees, (c) the importation, sale, offering for
sale, transport, distribution, promotion, marketing and manufacturing of
LIGHT-BASED DEVICES worldwide, (d) the limited purpose of (sub)contracting
activities that PALOMAR would have a right to perform directly hereunder,
subject to provisions safeguarding non-disclosure and non-use at least as strict
as those provided in this AGREEMENT, or (e) in connection with PALOMAR’s
entering into a THIRD PARTY COLLABORATION. In the event of the termination of
the license grant in Section 1.4.3, P&G shall have the right to terminate any
such sublicense. PALOMAR shall be responsible to P&G for the performance of any
of PALOMAR’s permitted sublicensees under Sections 1.4.2, 1.4.3, and 7.3.2 under
any provisions of this AGREEMENT for which PALOMAR is responsible. PALOMAR shall
not permit any sublicensees to use or disclose any P&G PROJECT KNOW-HOW without
provisions safeguarding non-disclosure and non-use at least as strict as those
provided in this AGREEMENT (including the rights to use and disclose same as
provided in Article 5). PALOMAR shall not have any right to assign any of the
licenses granted to PALOMAR hereunder, without P&G’s prior written consent,
provided that PALOMAR may assign such licenses in connection with the permitted
assignment of this AGREEMENT in full pursuant to Section 11.2.

1.6.  

License Limitations. With respect to the licenses granted herein, neither PARTY
shall EXPLOIT or practice any inventions, KNOW-HOW, PATENTS or REGULATORY
DOCUMENTATION licensed hereunder to such PARTY outside the scope of the
applicable license (including with respect to any field limitation).

**  

This material was omitted pursuant to a request for confidential treatment and
was separately filed with the SEC on March 3, 2008.

3

--------------------------------------------------------------------------------

1.7.  

No Other Licenses Granted. The licenses granted to P&G in this AGREEMENT are
limited to those specifically set forth in Sections 1.1, 1.2 and 1.4.1 and the
licenses granted to PALOMAR in this AGREEMENT are limited to those specifically
set forth herein. Nothing in this AGREEMENT is intended, or shall be construed,
to grant PALOMAR or P&G, as applicable, any other licenses in or to any PATENT,
KNOW-HOW, REGULATORY DOCUMENTATION or other intellectual property of the other
PARTY. All rights not specifically granted by a PARTY are reserved by such
PARTY.

1.8.  

**

2.

Development, Regulatory and Commercialization Matters

2.1.  

Development.

2.1.1.  

Control of Development Activities. P&G shall have the right to control any and
all development activities and decisions with respect to any and all LICENSED
PRODUCTS and NON-LIGHT-BASED PRODUCTS that P&G desires to EXPLOIT pursuant to
the licenses granted in Sections 1.1, 1.2 and 1.4.1. **

2.2.  

Regulatory Activities and Approvals.

2.2.1.  

Control of Regulatory Activities.

2.2.1.1.  

By P&G with Respect to LICENSED PRODUCTS and NON-LIGHT-BASED PRODUCTS. P&G (or
its designee) shall have the right to control any and all regulatory activities
and decisions with respect to any and all LICENSED PRODUCTS and NON-LIGHT-BASED
PRODUCTS that P&G desires to EXPLOIT pursuant to and consistent with the
licenses granted in Sections 1.1 and 1.2 in the FEMALE FIELD only and the
license granted in Section 1.4.1, respectively. Without limitation of the
foregoing, P&G shall have the right to obtain and maintain REGULATORY
APPROVAL(S) worldwide for LICENSED PRODUCTS and NON-LIGHT-BASED PRODUCTS that
P&G EXPLOITS pursuant to and consistent with the licenses granted in Sections
1.1 and 1.2 in the FEMALE FIELD only and the license granted in Section 1.4.1,
respectively. All REGULATORY DOCUMENTATION, and other filings, applications or
requests pursuant to or in connection with such REGULATORY APPROVALS worldwide,
shall be made in the name of P&G (or its designee). ** PALOMAR shall comply with
any audit requests regarding the LICENSED PRODUCTS sold by or on behalf of P&G,
made by any REGULATORY AUTHORITY to the extent required by applicable law, and
P&G shall reimburse PALOMAR for its reasonable out-of-pocket expenses in
connection with such compliance.

**  

This material was omitted pursuant to a request for confidential treatment and
was separately filed with the SEC on March 3, 2008.

4

--------------------------------------------------------------------------------

2.2.1.2.  

By PALOMAR with Respect to Certain LIGHT-BASED DEVICES. PALOMAR (or its
designee) shall have the right to control any and all regulatory activities and
decisions with respect to any and all LIGHT-BASED DEVICES that PALOMAR and its
permitted sublicensees desire to EXPLOIT pursuant to and consistent with any
licenses granted to PALOMAR hereunder. Without limitation of the foregoing,
PALOMAR and its permitted sublicensees shall have the right to obtain and
maintain REGULATORY APPROVAL(S) worldwide for LIGHT-BASED DEVICES that PALOMAR
and its permitted sublicensees EXPLOIT pursuant to and consistent with any
licenses granted to PALOMAR hereunder. All REGULATORY DOCUMENTATION, and other
filings, applications or requests pursuant to or in connection with such
REGULATORY APPROVALS worldwide, shall be made in the name of PALOMAR (or its
designee). P&G shall comply with any audit requests regarding the PALOMAR
REGULATORY DOCUMENTATION made by any REGULATORY AUTHORITY to the extent required
by applicable law, and PALOMAR shall reimburse P&G for its reasonable
out-of-pocket expenses in connection with such compliance.

2.2.2.  

**

2.2.3.  

FIRST FEMALE PRODUCT REGULATORY APPROVAL. The PARTIES acknowledge that, pursuant
to the ORIGINAL AGREEMENT, PALOMAR had the right to seek REGULATORY APPROVAL in
the United States for the FIRST FEMALE PRODUCT in PALOMAR’s name, and PALOMAR
sought and obtained such REGULATORY APPROVAL pursuant to PALOMAR’s 510(k)
notification K060839. **

2.3.  

Commercialization.

2.3.1.  

Of LICENSED PRODUCTS by P&G. P&G shall have the right to control any and all
commercialization activities and decisions with respect to any and all LICENSED
PRODUCTS that P&G desires to EXPLOIT pursuant to and consistent with the
licenses granted in Sections 1.1 and 1.2. Without limitation of the foregoing,
decisions relating to which technology shall be incorporated in, or used to
manufacture, LICENSED PRODUCTS, and P&G’s pricing of the LICENSED PRODUCTS,
shall be within the sole discretion of P&G and its permitted sublicensees.

2.3.2.  

Of LIGHT-BASED DEVICES by PALOMAR. PALOMAR shall have the right to control any
and all commercialization activities and decisions with respect to any and all
LIGHT-BASED DEVICES that PALOMAR and its permitted sublicensees desire to
EXPLOIT pursuant to and consistent with any licenses granted to PALOMAR
hereunder. Without limitation of the foregoing, decisions relating to which
technology shall be incorporated in, or used to manufacture, LIGHT-BASED
DEVICES, and PALOMAR’s and its permitted sublicensees' pricing of the
LIGHT-BASED DEVICES, shall be within the sole discretion of PALOMAR and its
permitted sublicensees.

**  

This material was omitted pursuant to a request for confidential treatment and
was separately filed with the SEC on March 3, 2008.

5

--------------------------------------------------------------------------------

 

2.3.3.  

Of NON-LIGHT-BASED PRODUCTS by P&G. P&G shall have the right to control any and
all commercialization activities and decisions with respect to any and all
NON-LIGHT-BASED PRODUCTS that P&G desires to EXPLOIT pursuant to and consistent
with the license granted in Section 1.4.1. Without limitation of the foregoing,
decisions relating to which technology shall be incorporated in, or used to
manufacture, NON-LIGHT-BASED PRODUCTS, and P&G’s pricing of the NON-LIGHT-BASED
PRODUCTS, shall be within the sole discretion of P&G and its permitted
sublicensees.

2.4.  

TRADEMARKS.

2.4.1.  

LICENSED PRODUCTS AND NON-LIGHT-BASED PRODUCTS. P&G shall have the sole right to
determine the TRADEMARKS (other than TRADEMARKS owned by PALOMAR) to be used
with respect to the EXPLOITATION of the LICENSED PRODUCTS and NON-LIGHT-BASED
PRODUCTS marketed by P&G and its permitted sublicensees, and shall own all
right, title and interest in and to such TRADEMARKS.

2.4.2.  

LIGHT-BASED DEVICES. PALOMAR shall have the sole right to determine the
TRADEMARKS (other than TRADEMARKS owned by P&G) to be used with respect to the
EXPLOITATION of the LIGHT-BASED DEVICES marketed by PALOMAR and its permitted
sublicensees, and shall own all right, title and interest in and to such
TRADEMARKS.

3.

 Payments & Reports

3.1.  

**

3.2.  

NOS-Based Payments. Subject to Section 3.1, P&G shall make NOS-based TTP and
royalty payments to PALOMAR, in each case with respect to the applicable
LICENSED PRODUCT(S) and TTP-BEARING PRODUCT(S), on such terms and conditions as
set forth in this Article 3. For illustration purposes only, such payments are
summarized in Table 3.2 below (provided that such amounts are subject to
applicable adjustments as provided in this Article 3). For the avoidance of
doubt, in the event of any conflict between this Section 3.2 and the other terms
and conditions of this Article 3, such other terms and conditions shall control.

Table 3.2**

3.3.  

TTP Payments

3.3.1.  

**

**  

This material was omitted pursuant to a request for confidential treatment and
was separately filed with the SEC on March 3, 2008.

6

--------------------------------------------------------------------------------

3.3.2.  

**. On a TTP-BEARING PRODUCT-by-TTP-BEARING PRODUCT basis, P&G shall pay to
PALOMAR TTPs in the amount of ** on that portion of worldwide NOS of each
TTP-BEARING PRODUCT **

3.3.3.  

**. On a TTP-BEARING PRODUCT-by-TTP-BEARING PRODUCT basis, P&G shall pay to
PALOMAR TTPs in the amount of ** on that portion of worldwide NOS of each
TTP-BEARING PRODUCT **.

3.3.4.  

Scope of TTP Obligation. For clarity, (a) no TTPs shall be payable by P&G
pursuant to Section 3.3.2 or 3.3.3 with respect to NOS of any LICENSED PRODUCT
TOPICAL, (b) only one TTP under Section 3.3.2 or 3.3.3 will be payable by P&G
with respect to any TTP-BEARING PRODUCT, and (c) P&G’s obligation to pay to
PALOMAR TTPs pursuant to Section 3.3.2 or 3.3.3 with respect to each TTP-BEARING
PRODUCT shall not commence until the first day of the TTP TERM and shall
terminate with respect to all TTP-BEARING PRODUCTS on the last day of the TTP
TERM. All TTPs shall be non-creditable and non-refundable and there shall be no
right of set-off with respect thereto.

3.3.5.  

TTP QUARTERLY PAYMENTS. Within thirty (30) days after the EXECUTION DATE, and
thereafter starting with the second QUARTER of 2008 within five (5) days after
the beginning of each QUARTER during the TERM up to and including the QUARTER in
which P&G LAUNCHES the first LICENSED PRODUCT anywhere in the world (but not for
any QUARTER thereafter), P&G shall pay to PALOMAR One Million Two Hundred and
Fifty Thousand Dollars (USD $1,250,000) as a QUARTERLY payment of TTPs payable
pursuant to this Section 3.3 (each, a “TTP QUARTERLY PAYMENT”). Each TTP
QUARTERLY PAYMENT shall be payable only once per QUARTER irrespective of the
number of LICENSED PRODUCTS that are developed or commercialized by P&G pursuant
to this AGREEMENT. TTP QUARTERLY PAYMENTS shall be non-creditable and
non-refundable and there shall be no right of set-off with respect thereto.

3.4.  

P&G Royalty Payments.

3.4.1.  

In General. On a LICENSED PRODUCT-by-LICENSED PRODUCT and country-by-country
basis, P&G shall pay to PALOMAR royalties in the amount of ** of NOS of each
LICENSED PRODUCT(S) in such country during the ROYALTY TERM ** where the
manufacture, sale, offer for sale, use or import of such LICENSED PRODUCT would
(in the absence of the license(s) provided pursuant to this AGREEMENT) infringe
a VALID CLAIM of a LICENSED PATENT in such country.

3.4.2.  

Scope of Royalty Obligation. For clarity, (a) only one royalty under this
Section 3.4 will be payable by P&G with respect to any LICENSED PRODUCT, despite
the existence of one or more VALID CLAIMS covering such LICENSED PRODUCT in any
country, and (b) P&G’s obligation to pay to PALOMAR royalties pursuant to
Section 3.4.1 shall not commence until the first day of the ROYALTY TERM for
such LICENSED PRODUCT with respect to a country and shall terminate on a
LICENSED PRODUCT-by-LICENSED PRODUCT and country-by-country basis on the last
date of the ROYALTY TERM for such LICENSED PRODUCT in such country. All royalty
payments made by P&G shall be non-creditable and non-refundable and there shall
be no right of set-off with respect thereto.

**  

This material was omitted pursuant to a request for confidential treatment and
was separately filed with the SEC on March 3, 2008.

7

--------------------------------------------------------------------------------

 

3.5.  

Combination Products. Notwithstanding anything contained in Sections 3.3 or 3.4,
in the event that a LICENSED PRODUCT is sold in any country in the form of a
combination product containing one or more products, devices, components,
accessories or TOPICALS that are not LICENSED PRODUCTS (“NON-PRODUCT
COMPONENTS”), then for purposes of calculating the amounts owed by P&G pursuant
to Sections 3.3 and 3.4 with respect thereto, NOS of such combination product
will be adjusted by multiplying actual NOS of such combination product in such
country calculated pursuant to the definition of NOS by a ratio of the list
prices to the trade for the product(s) at the start of each P&G FISCAL YEAR as
follows:

3.5.1.  

If the LICENSED PRODUCT(s) and the NON-PRODUCT COMPONENTS are each sold
separately in the United States, the ratio shall be A/(A+B), where A is the list
price to the trade in the United States on July 1 of the applicable P&G FISCAL
YEAR for the LICENSED PRODUCT(s), if sold separately, and B is list price to the
trade in the United States on July 1 of the applicable P&G FISCAL YEAR for the
NON-PRODUCT COMPONENTS, if sold separately.

3.5.2.  

If the NON-PRODUCT COMPONENTS in the combination product are not sold separately
in the United States, the ratio shall be A/C, where A is the list price to the
trade in the United States on July 1 of the applicable P&G FISCAL YEAR for the
LICENSED PRODUCT(s), if sold separately, and C is the list price to the trade of
such combination product in the United States.

3.5.3.  

If a LICENSED PRODUCT is not sold separately in the United States, the ratio
shall be (C-B)/C, where B is list price to the trade in the United States on
July 1 of the applicable P&G FISCAL YEAR for the NON-PRODUCT COMPONENTS in the
combination product, if sold separately, and C is the list price to the trade of
the combination product in the United States.

3.5.4.  

If, in the United States on July 1 of the applicable P&G FISCAL YEAR, neither
the LICENSED PRODUCT nor the NON-PRODUCT COMPONENTS are sold separately, a
market price for such LICENSED PRODUCT and such NON-PRODUCT COMPONENTS shall be
negotiated by the PARTIES in good faith.

 

For clarity, a container that is a LICENSED PRODUCT and the TOPICAL within such
container shall not be deemed a “combination product” for purposes of this
Section 3.5.

3.6.  

THIRD PARTY Royalties. In the event that P&G’s EXPLOITATION of any LICENSED
PRODUCTS under the license rights granted by PALOMAR to P&G under the LICENSED
PATENTS triggers any payment obligations to any THIRD PARTY pursuant to an
agreement originally entered into by PALOMAR and such THIRD PARTY prior to or on
the EFFECTIVE DATE, including to MGH pursuant to the MGH AGREEMENTS, PALOMAR
shall be solely responsible for such payments. In the event that P&G’s
EXPLOITATION of any LICENSED PRODUCTS under the license rights granted by
PALOMAR to P&G under the LICENSED PATENTS triggers any payment obligations to
any THIRD PARTY pursuant to an agreement originally entered into by PALOMAR and
such THIRD PARTY after the EFFECTIVE DATE, PALOMAR shall so inform P&G in
writing and provide to P&G a copy of such THIRD PARTY agreement (subject to any
confidentiality obligations). P&G shall be required to pay to PALOMAR any such
payment obligations attributable to P&G’s exercise of any rights or license (or
sublicense) under such THIRD PARTY agreement that accrue thirty (30) days after
P&G’s receipt of such agreement, and to otherwise abide by the applicable terms
and conditions of such THIRD PARTY agreement, in each case on such terms and in
such manner as PALOMAR reasonably determines will permit it to satisfy its
obligations to the THIRD PARTY under such agreement; provided, however, that in
the event that P&G elects not to exercise any rights or a license (or
sublicense) under such THIRD PARTY agreement, P&G shall so inform PALOMAR in
writing and from and after such date P&G shall have no rights or license (or
sublicense) and shall have no obligations to make such payments to PALOMAR for
such payment obligations that accrue after such date unless and until the
PARTIES otherwise mutually agree in writing.

8

--------------------------------------------------------------------------------

3.7.  

THIRD PARTY Royalties Owed by PALOMAR. In the event that PALOMAR’s EXPLOITATION
of any product or service under the license rights granted by P&G to PALOMAR
under the P&G LICENSED PATENTS in Section 7.3.2 triggers any payment obligations
by P&G to any THIRD PARTY, P&G shall so inform PALOMAR in writing and provide to
PALOMAR a copy of such THIRD PARTY agreement (subject to any confidentiality
obligations). PALOMAR shall be required to pay to P&G any such payment
obligations attributable to PALOMAR’s exercise of any rights or license (or
sublicense) under such THIRD PARTY agreement that accrue thirty (30) days after
PALOMAR’s receipt of such agreement, and to otherwise abide by the applicable
terms and conditions of such THIRD PARTY agreement, in each case on such terms
and in such manner as P&G reasonably determines will permit it to satisfy its
obligations to the THIRD PARTY under such agreement; provided, however, that in
the event that PALOMAR elects not to exercise any rights or a license (or
sublicense) under such THIRD PARTY agreement, PALOMAR shall so inform P&G in
writing and from and after such date PALOMAR shall have no such rights or
license (or sublicense) and shall have no obligation to make such payments to
P&G for such payment obligations that accrue after such date unless and until
the PARTIES otherwise mutually agree in writing.

3.8.  

TTP and Royalty Payments.

3.8.1.  

In General. Royalties and TTPs payable pursuant to Sections 3.3.2, 3.3.3 and
3.4.1 shall be payable on a QUARTERLY basis within sixty (60) days after the end
of each QUARTER, based upon the NOS during such QUARTER.

3.8.2.  

**

**  

This material was omitted pursuant to a request for confidential treatment and
was separately filed with the SEC on March 3, 2008.

9

--------------------------------------------------------------------------------

3.9.  

TTP and Royalty Statements. Each TTP and royalty payment hereunder (other than
the TTP QUARTERLY PAYMENTS) shall be accompanied by a statement showing (a) the
number of units of each LICENSED PRODUCT and TTP-BEARING PRODUCT sold by P&G on
a country-by-country basis during the applicable QUARTER, (b) the amount of
royalties and TTPs, if any, due on such NOS, (c) withholding taxes, if any,
required by applicable law to be deducted, (d) the date of the FIRST COMMERCIAL
SALE for each LICENSED PRODUCT in any country that occurred during the reporting
period, and (e) the exchange rates used in determining the amount of USD.

3.10.  

Records Retention; Audit.

3.10.1.  

Record Retention. ** P&G shall keep (and shall ensure that its agents and
sublicensees shall keep) records of such sales in sufficient detail to confirm
the accuracy of the TTP or royalty calculations hereunder. With respect to any
credits, offsets or other reductions (if any) taken against any TTP or royalty
or other payment, ** P&G shall keep (and shall ensure that its agents and
sublicensees shall keep) records of such credits, offsets or other reductions in
sufficient detail to confirm the accuracy of them hereunder.

3.10.2.  

Audit. Upon the written request of PALOMAR and not more than once in each P&G
FISCAL YEAR, P&G shall permit an independent accounting firm selected by
PALOMAR, and reasonably acceptable to P&G, at PALOMAR’s expense, to have access
during normal business hours, and upon reasonable prior written notice, to such
of the records of P&G as may be reasonably necessary to verify the accuracy of
the TTP or royalty reports hereunder **. The accounting firm shall disclose to
P&G and PALOMAR whether the royalty or reports are correct or incorrect and the
specific details concerning any discrepancies. No other information shall be
provided to PALOMAR.

3.10.3.  

Payment of Additional TTPs or Royalties. If such accounting firm concludes that
additional TTPs or royalties were owed during such period, or excess credits,
offsets or other reductions were taken, P&G shall pay the additional TTPs or
royalties, as applicable, with interest calculated as provided in Section 3.12
from the date originally due, within ** after the date on which such accounting
firm’s written report is delivered to P&G. If, and only if, the amount of the
underpayment is greater than **, then P&G shall reimburse PALOMAR for all costs
related to such audit.

3.10.4.  

Confidentiality. PALOMAR shall treat all information subject to review under
this Section 3.10 in accordance with the confidentiality provisions of Article 5
and shall cause its accounting firm to enter into a reasonably acceptable
confidentiality agreement with P&G obligating such firm to retain all such
financial information in confidence pursuant to such confidentiality agreement.

**  

This material was omitted pursuant to a request for confidential treatment and
was separately filed with the SEC on March 3, 2008.

10

--------------------------------------------------------------------------------

3.11.  

Mode of Payment. All payments to PALOMAR or P&G under this AGREEMENT shall be
made by deposit of USD in the requisite amount to such bank account as PALOMAR
may from time to time designate by notice to P&G. Payments shall be free and
clear of any taxes (other than withholding and other taxes imposed on PALOMAR,
which shall be for the account of PALOMAR), fees or charges, to the extent
applicable. With respect to sales outside the United States, payments shall be
calculated based on currency exchange rates for the QUARTER with respect to
which sales remittance is made for TTPs or royalties. For each month and each
currency, such exchange rate shall equal the arithmetic average of the bid and
ask rate for such currency obtained from Bloomberg at 1 a.m. Cincinnati time on
the last BUSINESS DAY of the month, or, if not so available, as otherwise agreed
by the PARTIES. Unless otherwise designated by PALOMAR in writing, all payments
to PALOMAR under this AGREEMENT shall be made by wire transfer to the following
bank account:

**

3.12.  

Interest on Late Payments. P&G shall pay interest to PALOMAR on the aggregate
amount of any payments that are not paid on or before the date such payments are
due under this AGREEMENT at a rate per annum equal to **.

3.13.  

Withholding. P&G shall use all reasonable and legal efforts to reduce tax
withholding on payments due PALOMAR hereunder. If P&G reasonably concludes that
tax withholdings under the laws of any country are required with respect to
payments to PALOMAR, P&G shall withhold the required amount and pay it to the
appropriate governmental entity. P&G shall cooperate with PALOMAR in the event
that PALOMAR claims exemption from such withholding or seeks deductions under
any double taxation or other similar treaty or agreement from time to time in
force, such cooperation to include, without limitation, P&G promptly providing
PALOMAR with original receipts or other evidence reasonably desirable and
sufficient to allow PALOMAR to document such withholdings.

3.14.  

Blocked Payments. In the event that, by reason of applicable law or regulation
in any country, it becomes impossible or illegal for P&G to transfer payments to
PALOMAR, such payments shall be deposited in local currency in the relevant
country to the credit of PALOMAR in a recognized banking institution designated
by PALOMAR or, if none is designated by PALOMAR within a period of thirty (30)
days after its receipt of written notice from P&G, in a recognized banking
institution selected by P&G and identified in a subsequent written notice given
to PALOMAR.

3.15.  

**

3.16.  

**

4.

 Intellectual Property

4.1.  

**

**  

This material was omitted pursuant to a request for confidential treatment and
was separately filed with the SEC on March 3, 2008.

11

--------------------------------------------------------------------------------

4.2.  

**

4.2.3.  

Records.. Solely for the purpose of complying with Section 4.2.2, PALOMAR and
P&G each shall maintain, or cause to be maintained, records of its respective
activities performed pursuant to the ORIGINAL AGREEMENT in sufficient detail and
in good scientific manner appropriate for patent and regulatory purposes, which
shall be complete and accurate and shall fully and properly reflect all work
done and results achieved in connection with those activities**. Each PARTY
shall have the right, during normal business hours and upon reasonable notice,
to inspect and copy any such records.

4.2.4.  

**

4.2.5.  

No Further Disclosure.. The PARTIES acknowledge that each PARTY has performed
its disclosure obligations with respect to PROJECT KNOW-HOW under this Agreement
through the EXECUTION DATE. As of and after the EXECUTION DATE, neither PARTY
shall be obligated to disclose to the other PARTY any PROJECT KNOW-HOW**.

4.3.  

Prosecution of PATENTS.

**

4.4.  

Enforcement of PATENTS.

**

4.5.  

PATENT Marking. Each PARTY shall mark, and shall cause all their agents and
(sub)licensees to mark, all products or systems made, used or sold under the
terms of this AGREEMENT, or their containers, in accordance with all applicable
United States patent-marking laws with respect to any PATENTS licensed to such
PARTY by the other PARTY under this AGREEMENT.

5.

 Confidentiality and Nondisclosure

5.1.  

Confidentiality Obligations.

5.1.1.  

General Obligations. Except as provided herein, during the TERM and for five (5)
years after this AGREEMENT’s termination pursuant to Article 7, each PARTY shall
hold in strict confidence and shall not publish or otherwise disclose, directly
or indirectly, to any THIRD PARTY (other than such PARTY’s employees, legal
counsel, consultants, auditors and advisors, collectively, “PERMITTED
CONFIDANTS”) any CONFIDENTIAL INFORMATION of the other PARTY. During such
period, a PARTY shall not use for any purpose, directly or indirectly,
CONFIDENTIAL INFORMATION of the other PARTY or its sublicensees furnished or
otherwise made known to it, except as licensed or otherwise permitted hereunder.
Except as provided herein, access to the disclosing PARTY’s CONFIDENTIAL
INFORMATION shall be restricted to PERMITTED CONFIDANTS of the receiving PARTY,
who, in each case, need to have access to carry out a permitted use. Each PARTY
shall cause its PERMITTED CONFIDANTS to abide by the applicable terms and
conditions of this Article 5. The CONFIDENTIAL INFORMATION, and all copies of
part or all thereof, shall be and remain the exclusive property of the
disclosing PARTY, and the receiving PARTY shall acquire only such licenses and
other rights as are expressly set forth in this AGREEMENT and only for as long
as such licenses and rights are in effect. Each PARTY shall promptly report to
the other any conduct relating to the other PARTY’s CONFIDENTIAL INFORMATION
inconsistent with the provisions of this Article 5, and take such action as may
be reasonably necessary and legally permissible to terminate such conduct. Each
PARTY shall reproduce and include the other PARTY’s proprietary rights notices
or reasonable equivalents when reproducing any item that contains the other
PARTY’s CONFIDENTIAL INFORMATION if the item bears such notices or reasonable
equivalents. Subject to Section 5.1.2, each PARTY shall be free to disclose its
own CONFIDENTIAL INFORMATION in its sole discretion.

**  

This material was omitted pursuant to a request for confidential treatment and
was separately filed with the SEC on March 3, 2008.

12

--------------------------------------------------------------------------------

 

5.1.2.  

Obligations With Respect to JOINT PROJECT TECHNOLOGY.1.1.1. Notwithstanding the
foregoing, the following terms and conditions shall apply with respect to JOINT
PROJECT TECHNOLOGY. JOINT PROJECT TECHNOLOGY shall not constitute the
CONFIDENTIAL INFORMATION of either PARTY, except to the extent any such
technology is expressly included in the definition of CONFIDENTIAL INFORMATION
provided in Section 5.3.1. With respect to any JOINT PROJECT TECHNOLOGY that
constitutes CONFIDENTIAL INFORMATION hereunder and does not fall entirely within
PALOMAR EXCLUSIVE PATENT LICENSES or the P&G EXCLUSIVE PATENT LICENSE, for such
period as such technology constitutes CONFIDENTIAL INFORMATION pursuant to
Section 5.3.1, each PARTY shall have the right (a) to EXPLOIT such CONFIDENTIAL
INFORMATION for any purpose, directly or indirectly (including the right to
grant licenses with respect thereto as contemplated in Section 4.1.3.2,
consistent with its rights as a joint owner thereof), and (b) to disclose such
CONFIDENTIAL INFORMATION to one or more THIRD PARTIES as permitted pursuant to
Section 5.2.

5.2.  

Permitted Disclosures. Each PARTY may disclose CONFIDENTIAL INFORMATION
(including the terms of this AGREEMENT) to the extent that such disclosure is:

5.2.1.  

Made in response to a valid order of a court of competent jurisdiction or other
supra-national, federal, national, regional, state, provincial or local
governmental or regulatory body of competent jurisdiction; provided, however,
that, except where impracticable for certain disclosures (e.g., in the event of
medical emergency), the receiving PARTY shall first have given notice to the
disclosing PARTY and given the disclosing PARTY a reasonable opportunity to
quash such order and to obtain a protective order requiring that the
CONFIDENTIAL INFORMATION and documents that are the subject of such order be
held in confidence by such court or agency or, if disclosed, be used only for
the purposes for which the order was issued; and provided further that if a
disclosure order is not quashed or a protective order is not obtained, the
CONFIDENTIAL INFORMATION disclosed in response to such court or governmental
order shall be limited to that information which is legally required to be
disclosed in response to such court or governmental order;

13

--------------------------------------------------------------------------------

5.2.2.  

Otherwise required by applicable law as reasonably determined by counsel to the
receiving PARTY;

5.2.3.  

Made by the receiving PARTY as may be reasonably necessary or useful to
prosecute or defend litigation, DISPUTES or other disputes between the PARTIES;

5.2.4.  

Made by the receiving PARTY to any REGULATORY AUTHORITY as required in
connection with any filing, application or request for REGULATORY APPROVAL (in
each case to the extent that using such CONFIDENTIAL INFORMATION of the other
PARTY in connection with seeking such approval is consistent with the rights and
licenses granted to the receiving PARTY hereunder); provided, however, that
reasonable measures shall be taken to assure confidential treatment of such
information to the extent practicable;

5.2.5.  

Made by the receiving PARTY or its sublicensees to THIRD PARTIES as may be
necessary or useful in connection with, in the case of P&G the EXPLOITATION of
LICENSED PRODUCTS in the FEMALE FIELD only or of NON-LIGHT-BASED PRODUCTS, or in
the case of PALOMAR the EXPLOITATION of LIGHT-BASED DEVICES in the fields
specified by the license grants by P&G to PALOMAR hereunder, as contemplated by
this AGREEMENT, including actual or potential (sub)licenses, THIRD PARTY
COLLABORATIONS and (sub)contracting transactions in connection therewith,
provided that such THIRD PARTIES shall be subject to obligations of
confidentiality and non-use with respect to such CONFIDENTIAL INFORMATION
substantially similar to the obligations of confidentiality and non-use that
apply to the PARTIES pursuant to this Article 5;

5.2.6.  

**

5.2.7.  

In the case of any JOINT PROJECT TECHNOLOGY that constitutes CONFIDENTIAL
INFORMATION and does not fall entirely within PALOMAR EXCLUSIVE PATENT LICENSES
or the P&G EXCLUSIVE PATENT LICENSE, made by a PARTY to a THIRD PARTY as may be
reasonably necessary or useful in connection with (a) preparing, filing,
prosecuting, maintaining, enforcing and defending JOINT PROJECT TECHNOLOGY; or
(b) the EXPLOITATION of the JOINT PROJECT TECHNOLOGY, directly or indirectly,
including by actual or potential (sub)licenses, THIRD PARTY COLLABORATIONS and
(sub)contracting transactions, provided that in the case of disclosures to THIRD
PARTIES pursuant to clause (b), such THIRD PARTIES shall be subject to
obligations of confidentiality and non-use with respect to such CONFIDENTIAL
INFORMATION substantially similar to the obligations of confidentiality and
non-use that apply to the PARTIES pursuant to this Article 5.

**  

This material was omitted pursuant to a request for confidential treatment and
was separately filed with the SEC on March 3, 2008.

14

--------------------------------------------------------------------------------

 

5.3.  

CONFIDENTIAL INFORMATION

5.3.1.  

Defined. “CONFIDENTIAL INFORMATION” of a PARTY shall mean all information and
KNOW-HOW provided by or on behalf of such PARTY to the other PARTY either in
connection with the discussions and negotiations pertaining to the ORIGINAL
AGREEMENT or this AGREEMENT or in the course of performing the ORIGINAL
AGREEMENT or this AGREEMENT, including data; knowledge; practices; processes;
ideas; research plans; engineering designs and drawings; research data;
manufacturing processes and techniques; scientific, manufacturing, marketing and
business plans; and financial and personnel matters relating to the disclosing
PARTY or to its present or future products, sales, suppliers, customers,
employees, investors or business. Without limiting the foregoing, subject to
Section 5.3.2, (a) CONFIDENTIAL INFORMATION of each PARTY shall include any and
all information provided by one PARTY to the other directly relating to LICENSED
PRODUCTS or NON-LIGHT- BASED PRODUCTS or LIGHT-BASED DEVICES, (b) CONFIDENTIAL
INFORMATION of both PARTIES shall include all JOINT PROJECT INVENTIONS until
such time as the PARTIES decline to pursue PATENT protection on them or until
the time for seeking PATENT protection has expired (and each PARTY shall be
regarded as the receiving PARTY for purposes of this Article 5 with respect to
any such CONFIDENTIAL INFORMATION, regardless of which PARTY discloses such
CONFIDENTIAL INFORMATION to the other), (c) CONFIDENTIAL INFORMATION of both
PARTIES shall include the terms of this AGREEMENT to the extent not publicly
disclosed as part of PALOMAR’s filing of this AGREEMENT with the SEC pursuant to
Section 5.6.2 (but, for clarity, not the terms of the ORIGINAL AGREEMENT to the
extent publicly disclosed prior to the EXECUTION DATE), (d) P&G CONFIDENTIAL
INFORMATION shall include all P&G REGULATORY DOCUMENTATION, P&G PROJECT
TECHNOLOGY and the subject matter of all other P&G LICENSED PATENTS (other than
JOINT PROJECT PATENTS) **, and (e) PALOMAR CONFIDENTIAL INFORMATION shall
include all PALOMAR REGULATORY DOCUMENTATION, PALOMAR TECHNOLOGY and the subject
1.1.1. matter of all LICENSED PATENTS (other than JOINT PROJECT PATENTS) **;
provided that notwithstanding the other terms of this definition, all
inventions, KNOW-HOW and PATENTS falling entirely within (i) the PALOMAR
EXCLUSIVE PATENT LICENSES shall be treated in all events as “PALOMAR
CONFIDENTIAL INFORMATION” hereunder (notwithstanding the ownership thereof) and
(ii) the P&G EXCLUSIVE PATENT LICENSE shall be treated in all events as “P&G
CONFIDENTIAL INFORMATION” hereunder (notwithstanding the ownership thereof).

**  

This material was omitted pursuant to a request for confidential treatment and
was separately filed with the SEC on March 3, 2008.

15

--------------------------------------------------------------------------------

        

5.3.2.  

Exclusions. Notwithstanding the foregoing, information or KNOW-HOW of a PARTY
shall not be deemed CONFIDENTIAL INFORMATION with respect to a receiving PARTY
for purposes of this AGREEMENT if such information or KNOW-HOW:

5.3.2.1.  

was already known to the receiving PARTY, other than under an obligation of
confidentiality or non-use, at the time of disclosure to, or, with respect to
KNOW-HOW, discovery or development by, such receiving PARTY;

5.3.2.2.  

was generally available or known, or was otherwise part of the public domain, at
the time of its disclosure to, or, with respect to KNOW-HOW, discovery or
development by, such receiving PARTY;

5.3.2.3.  

became generally available or known, or otherwise became part of the public
domain, after its disclosure to, or, with respect to KNOW-HOW, discovery or
development by, such receiving PARTY through no fault of a PARTY other than the
PARTY that CONTROLS such information and KNOW-HOW;

5.3.2.4.  

was disclosed to such receiving PARTY, other than under an obligation of
confidentiality or non-use, by a THIRD PARTY who had no obligation to the PARTY
that CONTROLS such information and KNOW-HOW not to disclose such information or
KNOW-HOW to others; or

5.3.2.5.  

was independently discovered or developed by such receiving PARTY, as evidenced
by its written records, without the use of CONFIDENTIAL INFORMATION belonging to
the PARTY that CONTROLS such information and KNOW-HOW.

5.4.  

Public Domain. Specific aspects or details of CONFIDENTIAL INFORMATION shall not
be deemed to be within the public domain or in the possession of a PARTY merely
because the CONFIDENTIAL INFORMATION is embraced by more general information in
the public domain or in the possession of such PARTY. Further, any combination
of CONFIDENTIAL INFORMATION shall not be considered in the public domain or in
the possession of a PARTY merely because individual elements of such
CONFIDENTIAL INFORMATION are in the public domain or in the possession of such
PARTY unless the combination and its principles are in the public domain or in
the possession of such PARTY.

5.5.  

Use of Name. Except as expressly permitted by Section 5.6, neither PARTY shall
use the name or any other insignia or TRADEMARK of the other PARTY (or any
abbreviation or adaptation thereof) in any publication, press release,
promotional material or other form of publicity without the prior written
approval of such other PARTY in each instance. Subject to Section 5.6, the
restrictions imposed by this Section shall not prohibit either PARTY from making
any disclosure identifying the other PARTY that is required by applicable law.

16

--------------------------------------------------------------------------------

5.6.  

Press Releases and SEC Filings.

5.6.1.  

FIRST PRESS RELEASE. On or after the EXECUTION DATE, each PARTY shall have the
right to issue a press release announcing this AGREEMENT in the form of Exhibit
C (the “FIRST PRESS RELEASE”).

5.6.2.  

  **

5.6.3.  

Other Public Disclosure Concerning Terms of AGREEMENT.1.1.1. Except as provided
in Sections 5.6.1 and 5.6.2, or as otherwise mutually agreed in advance in
writing by the PARTIES, neither PARTY shall issue a press release nor make any
other public disclosure concerning the terms of this AGREEMENT (to the extent
not publicly disclosed pursuant to Section 5.6.2), without the prior approval of
such press release or public disclosure by the other PARTY hereto. Each PARTY
shall submit any such press release or public disclosure to the other PARTY, and
such other PARTY shall have ** to review and approve any such press release or
public disclosure, which approval shall not be unreasonably withheld. Failure by
the other PARTY to approve such materials in writing within ** of its receipt of
same shall constitute disapproval, provided however, that if the PARTY wishing
to make such release does not receive a response to its request for approval of
submitted materials within the allotted **, it may notify the other PARTY in
writing that it has not yet received a response and the materials will be deemed
approved **. Notwithstanding the foregoing, each PARTY may make such public
disclosures as are reasonably required by applicable law as determined by
counsel to such PARTY.

5.6.4.  

Permitted Publicity. Notwithstanding the foregoing, each PARTY shall have the
right to publicly disclose any statements contained in the FIRST PRESS RELEASE
or in subsequent public disclosures permitted pursuant to Section 5.6.3 without
the prior consent or approval of the other PARTY.

5.7.  

Return of CONFIDENTIAL INFORMATION. Upon termination of this AGREEMENT for any
reason, each receiving PARTY, at such receiving PARTY’s election, shall return
or destroy (a) all CONFIDENTIAL INFORMATION provided in writing by the
disclosing PARTY to the receiving PARTY, and (b) copies of memoranda and notes
prepared by the receiving PARTY or any of its employees or agents that contain
CONFIDENTIAL INFORMATION of the disclosing PARTY; provided, however, that the
receiving PARTY may retain copies of such CONFIDENTIAL INFORMATION in which such
PARTY has a proprietary or licensed interest that survives termination;
provided, further, that the terms of clause (a) and clause (b) of this Section
5.7 shall not apply with respect to any CONFIDENTIAL INFORMATION contained in
reports to a PARTY’s board of directors or executive committees (or to the
extent reference is made thereto in board minutes or similar documents).
Notwithstanding the foregoing, the receiving PARTY and its legal counsel may
each retain a copy of such CONFIDENTIAL INFORMATION and memoranda and notes to
be used only in exercising the receiving PARTY’s rights and performing the
receiving PARTY’s obligations under this AGREEMENT, including in the case of a
dispute concerning this AGREEMENT.

**  

This material was omitted pursuant to a request for confidential treatment and
was separately filed with the SEC on March 3, 2008.

17

--------------------------------------------------------------------------------

 

The return or destruction of any CONFIDENTIAL INFORMATION will not relieve the
receiving PARTY of any of its obligations hereunder.

5.8.  

**

6.

  Termination of ORIGINAL AGREEMENT

6.1.  

Termination of ORIGINAL AGREEMENT. The ORIGINAL AGREEMENT shall hereby terminate
as of the EXECUTION DATE hereof, and such agreement is hereby superseded in its
entirety by this AGREEMENT.

6.2.  

Effects of Termination of ORIGINAL AGREEMENT. Notwithstanding anything contained
in the ORIGINAL AGREEMENT to the contrary, including Section 10.6, 10.7 and
10.10(b) thereof, no term or condition of the ORIGINAL AGREEMENT shall survive
the termination of such agreement as provided herein and the rights and
obligations of the PARTIES with respect to the subject matter contained in this
AGREEMENT shall be solely as set forth herein. For clarity, any amounts paid by
GILLETTE to PALOMAR pursuant to the terms of the ORIGINAL AGREEMENT prior to the
EXECUTION DATE shall be retained by PALOMAR.

7.

 Term and Termination of this AGREEMENT

7.1.  

Term. This AGREEMENT shall be deemed to take effect upon the EFFECTIVE DATE and
shall continue in effect until terminated in accordance with this Article 7
(such period, the “TERM”).

7.2.  

Rights of Termination.

7.2.1.  

Material Breach. Material failure by a PARTY to comply with any of its material
obligations contained herein shall entitle the PARTY not in default to give to
the PARTY in default notice specifying the nature of the default and requiring
the defaulting PARTY to cure such default. If such default is not cured within
**, or in the case of a default of any obligation to pay monies hereunder, **
(the “CURE PERIOD”) after the receipt of such notice (or, if such default cannot
be cured within the CURE PERIOD, if the PARTY in default does not commence
actions to cure such default within the CURE PERIOD and thereafter diligently
continue such actions), the PARTY not in default shall be entitled, without
prejudice to any of its other rights conferred on it by this AGREEMENT, and in
addition to any other remedies available to it by law or in equity, to terminate
this AGREEMENT in its entirety effective upon written notice to the defaulting
PARTY; provided, however, that any right to terminate under this Section 7.2.1
shall be stayed in the event that, during any CURE PERIOD, the PARTY alleged to
have been in default shall have initiated dispute resolution in accordance with
Article 10 with respect to the alleged default, which stay shall last so long as
the initiating PARTY diligently and in good faith cooperates in the prompt
resolution of such dispute resolution proceedings.

**  

This material was omitted pursuant to a request for confidential treatment and
was separately filed with the SEC on March 3, 2008.

18

--------------------------------------------------------------------------------

7.2.2.  

Unilateral Termination of this AGREEMENT by P&G. P&G shall have the right in its
sole discretion, with or without cause, to terminate this AGREEMENT in its
entirety by providing ** prior written notice to PALOMAR.**

7.2.3.  

Termination Upon Insolvency. Either PARTY may terminate this AGREEMENT if, at
any time, the other PARTY shall file in any court or agency pursuant to any
statute or regulation of any state, country or jurisdiction, a petition in
bankruptcy or insolvency or for reorganization or for an arrangement or for the
appointment of a receiver or trustee of that PARTY or of its assets, or if the
other PARTY shall be served with an involuntary petition against it, filed in
any insolvency proceeding, and such petition shall not be dismissed within **
after the filing thereof, or if the other PARTY shall propose or be a party to
any dissolution or liquidation, or if the other PARTY shall make an assignment
for the benefit of its creditors.

7.3.  

Effect of Termination. ** Subject to the last sentence in Section 7.2.2, in the
event that a PARTY terminates this AGREEMENT pursuant to Section 7.2, as of the
effective date of such termination, the following terms and conditions shall
apply.

7.3.1.  

Licenses. The licenses granted by PALOMAR to P&G in Sections 1.1 and 1.2 shall
terminate. All of the licenses granted by each of P&G and PALOMAR in Sections
1.4.1 and 1.4.2 shall survive any termination of this AGREEMENT. Except in the
case of termination of this AGREEMENT by P&G pursuant to Section 7.2.1 on
account of PALOMAR’s material breach or by P&G pursuant to Section 7.2.3, the
license granted by P&G in Section 1.4.3 shall survive termination of this
AGREEMENT.

7.3.2.  

License Under P&G LICENSED PATENTS and JOINT PROJECT PATENTS. In the event of
termination of this AGREEMENT (a) by PALOMAR pursuant to Section 7.2.1 on
account of P&G’s material breach or (b) by P&G pursuant to Section 7.2.2 or (c)
by PALOMAR pursuant to Section 7.2.3, in each case ((a) — (c)), prior to the
second (2nd) anniversary of the EXECUTION DATE, P&G shall be deemed to grant to
PALOMAR:

7.3.2.1.  

a worldwide, perpetual, royalty-free, irrevocable, non-exclusive right and
license, with the right to grant sublicenses (through multiple tiers of
sublicensing), under all of P&G’s right, title and interest in and to the P&G
LICENSED PATENTS (other than PATENTS exclusively licensed under Section 7.3.2.2)
to EXPLOIT products and processes in the FEMALE FIELD, and

7.3.2.2.  

a worldwide, perpetual, royalty-free, irrevocable, exclusive (including with
regard to P&G) right and license, with the right to grant sublicenses (through
multiple tiers of sublicensing), under all of P&G’s right, title and interest in
and to the JOINT PROJECT PATENTS **, and P&G PROJECT PATENTS ** to EXPLOIT
products and processes in the FEMALE FIELD, which license grants shall become
effective as of the effective date of such termination and shall be subject to
only the payment obligations of PALOMAR pursuant to Section 3.7. Further, within
** of such termination, P&G shall deliver a written notice to PALOMAR that
identifies in reasonable detail all P&G LICENSED PATENTS (including P&G PROJECT
PATENTS) that are subject to the foregoing license grant, as of the date of such
termination.

**  

 This material was omitted pursuant to a request for confidential treatment and
was separately filed with the SEC on March 3, 2008.

19

--------------------------------------------------------------------------------

7.3.3.  

Payments. All payment obligations of P&G, if any, pursuant to Article 3 shall
terminate, subject to Section 7.3.5.

7.3.4.  

Survival. The provisions listed in Section 7.5.3 (in addition to any provisions
designated in this Section 7.3 to survive termination) shall survive termination
of this AGREEMENT.

7.3.5.  

Authorized Sell-Off. Except in the case of termination of this AGREEMENT by
PALOMAR pursuant to Section 7.2.1 on account of P&G’s material breach (in which
event this Section 7.3.5 shall not apply), P&G shall have the right, during the
following ** (such period, the “SELL-OFF PERIOD”), to finish any
work-in-progress and to sell any inventory of LICENSED PRODUCTS that remains on
hand as of the date of the termination (and the completed work-in-progress);
provided, however, that P&G continues to pay applicable royalties and TTPs to
PALOMAR on all NOS of LICENSED PRODUCT during the SELL-OFF PERIOD in accordance
with the terms and conditions of this AGREEMENT.

7.4.  

Notice of Certain Sublicense Grants. In the event that PALOMAR grants to a THIRD
PARTY a sublicense under the license granted by P&G to PALOMAR in Section 7.3.2,
PALOMAR shall promptly provide to P&G written notice of such grant and the
identity of the THIRD PARTY, together with copies of those provisions of such
AGREEMENT that relate directly to the P&G LICENSED PATENTS so sublicensed (e.g.,
license grant provisions and intellectual property provisions relating to patent
prosecution and enforcement rights).

7.5.  

Accrued Rights; Rights Cumulative; Surviving Obligations.

7.5.1.  

Accrued Rights. Termination of this AGREEMENT for any reason shall be without
prejudice to any rights that shall have accrued to the benefit of a PARTY prior
to such termination. Such termination shall not relieve a PARTY from obligations
that are expressly indicated to survive the termination of this AGREEMENT.

7.5.2.  

Rights Cumulative. The rights and remedies set forth in this AGREEMENT are
cumulative and in addition to any other rights or remedies that may be available
to a PARTY hereunder.

7.5.3.  

Survival. 1.1.1. Subject to and without limiting anything contained in this
Article 7, Sections 1.2.2, 1.3 (other than the first sentence thereof), 1.4.1,
1.4.2, 1.5 (other than the first sentence thereof), 1.6, 1.7, 2.1.2, 2.2.1.2,
2.2.2, 2.3.2, 2.3.3, 2.4, 3.7, 3.8.2, 3.10 and 3.12, the last sentence of
Section 2.1.1, and Articles 4, 5, 6, 7, 8, 10 and 11 of this AGREEMENT shall
survive the termination of this AGREEMENT for any reason; all other provisions
shall terminate on any such termination of this AGREEMENT.

**  

This material was omitted pursuant to a request for confidential treatment and
was separately filed with the SEC on March 3, 2008.

20

--------------------------------------------------------------------------------

 

7.6.  

Rights in Bankruptcy. All rights and licenses granted under or pursuant to this
AGREEMENT by P&G or PALOMAR are, and shall otherwise be deemed to be, for
purposes of Section 365(n) of the United States Bankruptcy Code, licenses of
rights to “intellectual property” as defined under Section 101 of the United
States Bankruptcy Code. The PARTIES, as licensees of such rights under this
AGREEMENT, shall retain and may fully exercise all of their rights and elections
under the United States Bankruptcy Code. In the event of the commencement of a
bankruptcy proceeding by or against either PARTY under the United States
Bankruptcy Code, the PARTY hereto that is not a party to such proceeding shall
be entitled to a complete duplicate of (or complete access to, as appropriate)
any such intellectual property and all embodiments of such intellectual
property, which, if not already in the non-subject PARTY’s possession, shall be
promptly delivered to it (a) upon any such commencement of a bankruptcy
proceeding upon the non-subject PARTY’s written request therefor, unless the
PARTY subject to such proceeding elects to continue to perform all of its
obligations under this AGREEMENT or (b) if not delivered under clause (a) above,
following the rejection of this AGREEMENT by or on behalf of the PARTY subject
to such proceeding upon written request therefor by the non-subject PARTY.

8.  

**

8.1.  

**

8.2.  

**

8.3.  

**

8.4.  

Limitation on Damages and Liability.

8.4.1.  

LIMITATION ON DAMAGES. SUBJECT TO SECTIONS 8.1 AND 8.2, AND EXCEPT IN
CIRCUMSTANCES OF GROSS NEGLIGENCE OR INTENTIONAL MISCONDUCT, NEITHER P&G NOR
PALOMAR SHALL BE LIABLE FOR SPECIAL, INDIRECT, PUNITIVE, INCIDENTAL OR
CONSEQUENTIAL DAMAGES (INCLUDING FOR LOST PROFITS, DEVELOPMENT COMPLETION OR
ROYALTIES), WHETHER IN CONTRACT, WARRANTY, NEGLIGENCE, TORT, STRICT LIABILITY OR
OTHERWISE, ARISING OUT OF (a) THE EXPLOITATION OF ANY PRODUCT OR SYSTEM
EXPLOITED HEREUNDER, (b) ANY BREACH OF OR FAILURE TO PERFORM ANY OF THE
PROVISIONS OF THIS AGREEMENT, OR (c) OTHERWISE RELATING TO THIS AGREEMENT, EVEN
IF SUCH PARTY HAS BEEN INFORMED OR SHOULD HAVE KNOWN OF THE POSSIBILITY OF SUCH
DAMAGES.

8.4.2.  

DISCLAIMER

**  

This material was omitted pursuant to a request for confidential treatment and
was separately filed with the SEC on March 3, 2008.

21

--------------------------------------------------------------------------------

8.4.2.1.  

BY P&G. EXCEPT AS OTHERWISE EXPRESSLY PROVIDED IN THIS AGREEMENT, (a) P&G HEREBY
DISCLAIMS ANY AND ALL WARRANTIES, WHETHER WRITTEN OR ORAL, OR EXPRESS OR
IMPLIED, WITH RESPECT TO THE P&G LICENSED PATENTS, PROJECT TECHNOLOGY, P&G
CONFIDENTIAL INFORMATION, AND P&G REGULATORY DOCUMENTATION, INCLUDING ANY
WARRANTY OF QUALITY, TITLE, NONINFRINGEMENT, PERFORMANCE, MERCHANTABILITY OR
FITNESS FOR A PARTICULAR USE OR PURPOSE, AND (b) WITHOUT LIMITING THE FOREGOING,
P&G EXPRESSLY DISCLAIMS ANY EXPRESS OR IMPLIED WARRANTY OR REPRESENTATION (i) AS
TO THE VALIDITY OR SCOPE OF ANY OF THE INTELLECTUAL PROPERTY RIGHTS LICENSED BY
P&G HEREUNDER, (ii) THAT ANY LICENSED PRODUCTS, ANY OTHER PRODUCTS OR ANY
ACTIVITIES OF THE PARTIES CONTEMPLATED BY THIS AGREEMENT, SHALL BE FREE FROM
INFRINGEMENT, MISAPPROPRIATION OR MISUSE OF ANY THIRD PARTY INTELLECTUAL
PROPERTY RIGHTS, OR (iii) AS TO THE QUALITY OR PERFORMANCE OF ANY INFORMATION
AND INVENTIONS OR LICENSED PRODUCTS OR ANY OTHER PRODUCTS.

8.4.2.2.  

BY PALOMAR. EXCEPT AS OTHERWISE EXPRESSLY PROVIDED IN THIS AGREEMENT,
(a) PALOMAR HEREBY DISCLAIMS ANY AND ALL WARRANTIES, WHETHER WRITTEN OR ORAL, OR
EXPRESS OR IMPLIED, WITH RESPECT TO THE PALOMAR TECHNOLOGY, PROJECT TECHNOLOGY,
PALOMAR CONFIDENTIAL INFORMATION, AND PALOMAR REGULATORY DOCUMENTATION,
INCLUDING ANY WARRANTY OF QUALITY, TITLE, NONINFRINGEMENT, PERFORMANCE,
MERCHANTABILITY OR FITNESS FOR A PARTICULAR USE OR PURPOSE, AND (b) WITHOUT
LIMITING THE FOREGOING, PALOMAR EXPRESSLY DISCLAIMS ANY EXPRESS OR IMPLIED
WARRANTY OR REPRESENTATION (i) AS TO THE VALIDITY OR SCOPE OF ANY OF THE
INTELLECTUAL PROPERTY RIGHTS LICENSED HEREUNDER, (ii) THAT ANY LICENSED
PRODUCTS, ANY OTHER PRODUCTS OR ANY ACTIVITIES OF THE PARTIES CONTEMPLATED BY
THIS AGREEMENT, SHALL BE FREE FROM INFRINGEMENT, MISAPPROPRIATION OR MISUSE OF
ANY THIRD PARTY INTELLECTUAL PROPERTY RIGHTS, OR (iii) AS TO THE QUALITY OR
PERFORMANCE OF ANY INFORMATION AND INVENTIONS OR LICENSED PRODUCTS OR ANY OTHER
PRODUCTS.

8.5.  

Insurance. Each PARTY agrees to maintain during the TERM such insurance coverage
or program of self-insurance as is commercially reasonable, taking into
consideration the activities and other circumstances of such PARTY. If at any
time PALOMAR sells or distributes any products pursuant to a license granted by
P&G to PALOMAR in this AGREEMENT, or other products that use, embody, are
manufactured using, practice an invention claimed by, comprise or are comprised
of, in whole or in part, PROJECT TECHNOLOGY or the subject matter of any P&G
LICENSED PATENTS, in each case optionally with one or more THIRD PARTIES, P&G
shall have the right to request that PALOMAR increase the scope and extent of
its coverage and to the extent that such request(s) is commercially reasonable,
PALOMAR shall comply with such request and obtain such additional coverage.

22

--------------------------------------------------------------------------------

9.  

**

10.

  Dispute Resolution

10.1.  

In General. If a dispute arises between the PARTIES in connection with or
relating to this AGREEMENT or any document or instrument delivered in connection
herewith (including any INVENTORSHIP DISPUTE, each a “DISPUTE”), the PARTIES
shall use the procedures set forth in Sections 10.2, 10.3 and 10.4 to resolve
such DISPUTE(S).

10.2.  

Internal Escalation. A meeting shall be held between the PARTIES within ten (10)
days after either PARTY gives written notice of a DISPUTE to the other PARTY
(the “DISPUTE NOTICE”). The meeting shall be attended by a representative of
each PARTY having decision-making authority regarding the DISPUTE (subject to
Board of Directors or equivalent approval, if required), who shall attempt in
good faith to negotiate a resolution of the DISPUTE.

10.3.  

DISPUTES.

10.3.1.  

Mediation. In the event that representatives of the PARTIES are unable to
resolve a DISPUTE pursuant to Section 10.2 within thirty (30) days of the
meeting contemplated by such Section, either PARTY may, by written notice to the
other, invoke the following mediation. The PARTIES shall try in good faith to
resolve such dispute by mediation administered by the Center for Public
Resources (“CPR”), provided that specific provisions of this Section 10.3.1
shall override inconsistent provisions of the applicable CPR mediation rules.
The mediator shall be selected from the CPR Panel of Neutrals and the location
of the mediation shall be in Boston, Massachusetts. If the PARTIES cannot agree
upon the selection of the mediator, then CPR shall appoint the mediator. The
PARTIES shall attempt to resolve such DISPUTE through mediation until one of the
following occurs: (a) the PARTIES reach a written settlement; (b) the mediator
notifies the PARTIES in writing that they have reached an impasse; (c) the
PARTIES agree in writing that they have reached an impasse; or (d) the PARTIES
have not reached a settlement within forty-five (45) days of the initiation of
the mediation. All aspects of any such mediation, including any resolution or
decision relating thereto, shall be confidential and all participants, including
the mediator, shall be bound by judicially enforceable obligations of strict
confidentiality except to the extent the PARTIES agree in writing to waive in
whole or part such confidentiality.

**  

This material was omitted pursuant to a request for confidential treatment and
was separately filed with the SEC on March 3, 2008.

23

--------------------------------------------------------------------------------

10.3.2.  

Judicial Remedies. Except with respect to INVENTORSHIP DISPUTES, which are
subject to Section 10.4, if the PARTIES have not succeeded in negotiating a
written resolution of the DISPUTE after following the procedures specified in
Sections 10.2 and 10.3, either PARTY may exercise any and all of its judicial
rights and remedies to resolve such DISPUTE.

10.4.  

DISPUTES Regarding Inventorship of PROJECT INVENTIONS. In the event of a DISPUTE
between the PARTIES concerning the inventorship of any PROJECT INVENTIONS,
whether or not subject to the Section 4.2.2 process (an “INVENTORSHIP DISPUTE”),
the following procedures shall apply.

10.4.1.  

Mediation. The PARTIES shall engage in the process set forth in Sections 10.2
and 10.3.1 with respect to such INVENTORSHIP DISPUTE.

10.4.2.  

In General. In the event that the PARTIES have not succeeded in negotiating a
written resolution of the INVENTORSHIP DISPUTE are unable to resolve an
INVENTORSHIP DISPUTE after following the procedures specified in Sections 10.2
and 10.3.1, either PARTY may, by written notice to the other, initiate
arbitration (“ADR”) through CPR, provided that specific provisions of this
Section 10.4 shall override inconsistent provisions or procedures under the
applicable ADR rules.

10.4.3.  

Appointment of a Panel of NEUTRALS. Within fifteen (15) days following the
initiation of ADR, (a) each PARTY shall promptly select a disinterested,
neutral, conflict-free patent attorney not affiliated with either PARTY who
possesses the requisite legal, scientific and technical expertise to understand
the legal and technical issues necessary to review and determine the
inventorship of applicable PROJECT INVENTION(S) (each a “NEUTRAL”), and (b) the
PARTIES shall negotiate in good faith to select a mutually acceptable third
NEUTRAL. If the PARTIES are not able to agree on an acceptable third NEUTRAL
within thirty (30) days after the initiation of ADR, at the request of either
PARTY after the conclusion of such period, CPR shall be responsible for
selecting a third NEUTRAL within fifteen (15) days of such request.

10.4.4.  

Procedures. The panel of NEUTRALS shall conduct the ADR in accordance with the
terms and conditions of this Section 10.4 and the fees and costs of the NEUTRALS
and CPR shall be shared equally by the PARTIES. Within sixty (60) days after
such matter is referred to ADR, each PARTY shall simultaneously submit to the
panel of NEUTRALS (a) a statement regarding each PARTY’s contentions as to the
inventorship of each PROJECT INVENTION as to which there is a question regarding
inventorship, together with a description of such PARTY’s evidentiary support
for its contentions and (b) a request for any discovery such PARTY believes to
be necessary and appropriate for determining the inventorship of PROJECT
INVENTIONS. Each PARTY may, within fifteen (15) days after the date of receipt
of the other PARTY’s discovery request, provide a written statement consenting
or objecting to the requests made by the other PARTY, setting forth a concise
statement in support of any such objections. Within five (5) days after the
receipt of such statements, the panel of NEUTRALS shall determine by majority
vote whether to require that the PARTIES provide any such discovery, including
the production of documents and the taking of depositions, as the panel of
NEUTRALS determines in its discretion to be reasonably necessary and appropriate
under the circumstances, taking into consideration the PARTIES’ desires to
conclude the inventorship review expeditiously, and shall provide an expedited
schedule that sets forth the dates by which such discovery is to be completed.
The NEUTRALS’ schedule shall require that such discovery be completed no later
than forty-five (45) days after the date such schedule is issued to the PARTIES
(or such shorter period as the panel of NEUTRALS may provide in such schedule).
In requiring the conduct of discovery under this Section 10.4.4, the panel of
NEUTRALS, at the request of a PARTY, may require that documents and information
provided by one PARTY to the other PARTY in the course of such discovery be
treated as the “CONFIDENTIAL INFORMATION” of the disclosing PARTY, as such term
is used in this AGREEMENT, in which event such documents and information shall
be subject to Section 5.1 hereof, without giving effect to Section 5.2.

24

--------------------------------------------------------------------------------

10.4.5.  

Submission of Written Statement. Within forty-five (45) days after the
completion of any discovery required by the panel of NEUTRALS in accordance with
any schedule issued pursuant to Section 10.4.4, the PARTIES shall each
simultaneously submit to the panel of NEUTRALS and one another (a) a written
statement, not exceeding any limits in length which may be established at the
discretion of the panel of NEUTRALS, of their respective positions with respect
to the inventorship of the applicable PROJECT INVENTIONS, which shall include
any factual, scientific and technical information in support thereof and (b) any
modifications or supplements to statement of contentions and evidentiary support
submitted by such PARTY pursuant to Section 10.4.4. Each PARTY may within thirty
(30) days from the date of receipt of the other PARTY’s statement submit to the
panel of NEUTRALS and other PARTY a written reply. As determined by the majority
vote of the panel of NEUTRALS, in the panel’s sole discretion, to be reasonably
necessary in order to review and determine the inventorship of the applicable
PROJECT INVENTIONS, (i) the panel of NEUTRALS shall meet with the PARTIES,
either alone or together, and (ii) each PARTY shall appear voluntarily, and
cause its employees and agents to appear voluntarily, at any hearing(s) before
the panel of NEUTRALS and to give voluntarily sworn testimony before such panel;
provided, however, that all such meetings and hearings shall be conducted in
Boston, Massachusetts, or such other location as the PARTIES may agree, and
completed within an additional forty-five (45) period beginning seventy-five
(75) days following the completion of any discovery required by the panel of
NEUTRALS in accordance with any schedule issued pursuant to Section 10.4.4. No
later than thirty (30) days from the end of such forty-five (45) day period, by
majority vote, the panel of NEUTRALS shall make a determination of the
inventorship of the applicable PROJECT INVENTIONS and provide the PARTIES with a
written statement setting forth such determination in detail together with the
basis for same. The PARTIES agree that such determination of the NEUTRALS shall
be final, conclusive and binding on the PARTIES. The determination of the panel
of NEUTRALS shall be enforceable in accordance with the applicable law relating
to the enforcement of arbitration awards, and the determination may not be
appealed or set aside for any reason other than fraud or other misconduct by a
NEUTRAL, in which case the determination may be challenged in accordance with
law applying to challenges to arbitration awards.

25

--------------------------------------------------------------------------------

10.4.6.  

Implementation of NEUTRALS’ Determination. Upon receipt of the NEUTRALS’
determination, the PARTIES shall take all appropriate actions to promptly
implement the determination of the NEUTRALS as appropriate in the continued
prosecution of the PATENTS for the applicable PROJECT INVENTIONS.

10.5.  

Tolling. The PARTIES agree that all applicable statutes of limitation and
time-based defenses (such as estoppel and laches) shall be tolled while the
procedures set forth in this Article 10 are pending, and the PARTIES shall
cooperate in taking any and all actions necessary to achieve such a result.

10.6.  

Interim Relief. Notwithstanding anything herein to the contrary, nothing in this
Article 10 shall preclude either PARTY from seeking interim or provisional
relief, including a temporary restraining order, preliminary injunction or other
interim equitable relief concerning a DISPUTE, either prior to or during the
applicable mediation, if necessary to protect the interests of such PARTY. This
Section 10.6 shall be specifically enforceable.

11.

  Miscellaneous

11.1.  

Force Majeure. Neither PARTY shall be held liable or responsible to the other
PARTY or be deemed to have defaulted under or breached this AGREEMENT for
failure or delay in fulfilling or performing any term of this AGREEMENT when
such failure or delay is caused by or results from causes beyond the reasonable
control of the non-performing PARTY, including fires, floods, earthquakes,
embargoes, shortages, epidemics, quarantines, war, acts of war (whether war be
declared or not), acts of terrorism, insurrections, riots, civil commotion,
strikes, lockouts or other labor disturbances, acts of God or acts, omissions or
delays in acting by any governmental authority. The non-performing PARTY shall
notify the other PARTY of such force majeure within ten (10) days after such
occurrence by giving written notice to the other PARTY stating the nature of the
event, its anticipated duration, and any action being taken to avoid or minimize
its effect. The suspension of performance shall be of no greater scope and no
longer duration than is necessary and the non-performing PARTY shall use
commercially reasonable efforts to remedy its inability to perform; provided,
however, that in the event the suspension of performance continues for
one-hundred and eighty (180) days after the date of the occurrence, and such
failure to perform would constitute a material breach of this AGREEMENT in the
absence of such force majeure, the performing PARTY may terminate this AGREEMENT
pursuant to Section 7.2.1 by written notice to the other PARTY.

11.2.  

Assignment; Change of Control.

11.2.1.  

Assignment. Without the prior written consent of the other PARTY hereto, neither
PARTY shall sell, transfer, assign, delegate, pledge or otherwise dispose of,
whether voluntarily, involuntarily, by operation of law or otherwise, this
AGREEMENT or any of its rights or duties hereunder; provided, however, that
either PARTY may, without such consent, and upon written notice to the other
PARTY, assign this AGREEMENT and its rights and obligations hereunder to (a) an
AFFILIATE, or (b) an ACQUIRING PARTY in the event of a CHANGE OF CONTROL of such
PARTY. Any attempted assignment or delegation in violation of the immediately
preceding sentence shall be void and of no effect. All validly assigned and
delegated rights and obligations of the PARTIES hereunder shall be binding upon
and inure to the benefit of and be enforceable by and against the successors and
permitted assigns of P&G or PALOMAR, as the case may be. In the event either
PARTY seeks and obtains the other PARTY’s consent to assign or delegate its
rights or obligations to another PARTY, the assignee or transferee shall assume
all obligations of its assignor or transferor under this AGREEMENT.

26

--------------------------------------------------------------------------------

11.2.2.  

ACQUIRING PARTY Intellectual Property. In the event of any CHANGE OF CONTROL of
a PARTY, (a) no PATENTS or other intellectual property rights of the ACQUIRING
PARTY or its affiliates shall be deemed “CONTROLLED” for any purpose hereunder
if such PATENTS or other intellectual property rights were not so CONTROLLED by
the acquired PARTY prior to such assignment, and (b) any contractual
restrictions on the PATENTS or other intellectual property rights of the
acquired PARTY shall be binding on the ACQUIRING PARTY.

11.2.3.  

**

11.3.  

Severability. If any provision of this AGREEMENT is held to be illegal, invalid
or unenforceable under any present or future law, and if the rights or
obligations of any PARTY under this AGREEMENT will not be materially and
adversely affected thereby, (a) such provision shall be fully severable, (b)
this AGREEMENT shall be construed and enforced as if such illegal, invalid or
unenforceable provision had never compromised a part hereof, (c) the remaining
provisions of this AGREEMENT shall remain in full force and effect and shall not
be affected by the illegal, invalid or unenforceable provision or by its
severance herefrom, and (d) in lieu of such illegal, invalid or unenforceable
provision, there shall be added automatically as a part of this AGREEMENT a
legal, valid and enforceable provision as similar in terms to such illegal,
invalid or unenforceable provision as may be possible and reasonably acceptable
to the PARTIES herein. To the fullest extent permitted by applicable law, each
PARTY hereby waives any provision of law that would render any provision hereof
prohibited or unenforceable in any respect.

11.4.  

Governing Law. This AGREEMENT shall be governed by and construed in accordance
with the laws of The Commonwealth of Massachusetts, without reference to the
rules of conflict of laws thereof, provided that any dispute relating to the
scope, validity, enforceability or infringement of any PATENT or other
intellectual property rights shall be governed by, and construed and enforced in
accordance with, the substantive laws of the jurisdiction in which such PATENTS
or other right applies.

11.5.  

Notices. All notices or other communications that are required or permitted
hereunder shall be in writing and delivered personally, sent by facsimile (and
promptly confirmed by personal delivery, registered or certified mail or
overnight courier as provided herein), sent by nationally-recognized overnight
courier or sent by registered or certified mail, postage prepaid, return receipt
requested, addressed as follows:

**  

This material was omitted pursuant to a request for confidential treatment and
was separately filed with the SEC on March 3, 2008.

27

--------------------------------------------------------------------------------

 

If to PALOMAR, to:   Palomar Medical Technologies, Inc. 82 Cambridge Street
Burlington, MA 01803 Attention: President & General Counsel Facsimile: (781)
993-2300

With a copy to:   Goodwin | Procter LLP Exchange Place 53 State Street Boston,
Massachusetts 02109 Attention: Kingsley L. Taft, Esq. Facsimile: (617) 523-1231

If to P&G, to:   The Procter & Gamble Company Two P&G Plaza Cincinnati, OH 45202
Attn: Vice President, External Business Development Facsimile: (513) 983-0912

With a copy to:   Covington & Burling LLP One Front Street San Francisco,
California 94111 Attention: Jim Snipes and Emily Leonard Facsimile: (415)
591-6091

With a copy to:   The Gillette Company 4800 Prudential Tower Building Boston,
Massachusetts 02199 Attn: General Counsel Facsimile: (617) 421-7874

 

or to such other address as the PERSON to whom notice is to be given may have
furnished to the other PERSON in writing in accordance herewith. Any such
communication shall be deemed to have been given (a) when delivered, if
personally delivered or sent by facsimile on a BUSINESS DAY, (b) on the BUSINESS
DAY after dispatch, if sent by nationally-recognized overnight courier, and (c)
on the third BUSINESS DAY following the date of mailing, if sent by mail. It is
understood and agreed that this Section 11.5 is not intended to govern the
day-to-day business communications necessary between the PARTIES in performing
their duties, in due course, under the terms of this AGREEMENT.

28

--------------------------------------------------------------------------------

11.6.  

Export Control. Notwithstanding anything else herein, neither PARTY shall
directly or indirectly export or re-export any LICENSED PRODUCT, JOINT PROJECT
TECHNOLOGY, PALOMAR TECHNOLOGY, P&G LICENSED PATENTS or CONFIDENTIAL INFORMATION
of the other PARTY, or any direct product of any of the foregoing, outside the
United States, without complying with all applicable U.S. and foreign export
control and other laws and regulations (including providing the other PARTY any
required assurance regarding export and re-export).

11.7.  

Entire AGREEMENT; Modifications. Other than the NON-DISCLOSURE AGREEMENT, which
is addressed in Section 5.8, and the ORIGINAL AGREEMENT, which is addressed in
Article 6, this AGREEMENT sets forth and constitutes the entire agreement and
understanding between the PARTIES with respect to the subject matter hereof and
all prior agreements, understandings, promises and representations, whether
written or oral, with respect thereto are superseded hereby. Each PARTY confirms
that it is not relying on any representations or warranties of the other PARTY
except as specifically set forth herein. No amendment, modification, release or
discharge hereof shall be binding upon the PARTIES unless in writing and duly
executed by authorized representatives of both PARTIES.

11.8.  

Relationship of the PARTIES. It is expressly agreed that PALOMAR, on the one
hand, and P&G, on the other hand, shall be independent contractors and that the
relationship between the two PARTIES shall not constitute a partnership, joint
venture or agency. Neither PALOMAR, on the one hand, nor P&G, on the other hand,
shall have the authority to make any statements, representations or commitments
of any kind, or to take any action, which shall be binding on the other, without
the prior written consent of the other PARTY to do so and no such statements,
representations or commitments shall be construed so as to require either PARTY
to expend either funds or efforts or commit resources in excess of those
expressly contemplated by this AGREEMENT. All persons employed by a PARTY shall
be employees of such PARTY and not of the other PARTY and all costs and
obligations incurred by reason of any such employment shall be for the account
and expense of such PARTY.

11.9.  

Waiver. Any term or condition of this AGREEMENT may be waived at any time by the
PARTY that is entitled to the benefit thereof, but no such waiver shall be
effective unless set forth in a written instrument duly executed by or on behalf
of the PARTY waiving such term or condition. The waiver by either PARTY hereto
of any right hereunder or of the failure to perform or of a breach by the other
PARTY shall not be deemed a waiver of any other right hereunder or of any other
breach or failure by said other PARTY whether of a similar nature or otherwise.

11.10.  

Counterparts. This AGREEMENT may be executed in two (2) or more counterparts,
and by different PARTIES on separate counterparts, each of which shall be deemed
an original, but all of which together shall constitute one and the same
instrument. Delivery of an executed counterpart of a signature page of this
AGREEMENT by facsimile or other electronic transmission shall be effective as
delivery of a manually executed original counterpart of this AGREEMENT.

29

--------------------------------------------------------------------------------

 11.11  

No Benefit to THIRD PARTIES. ** the representations, warranties, covenants and
agreements set forth in this AGREEMENT are for the sole benefit of the PARTIES
hereto and their successors and permitted assigns, and they shall not be
construed as conferring any rights on any other PERSONS.

11.12.  

Further Assurance. Each PARTY shall duly execute and deliver, or cause to be
duly executed and delivered, such further instruments and do and cause to be
done such further acts and things, including the filing of such assignments,
agreements, documents and instruments, as may be necessary or as the other PARTY
may reasonably request in connection with this AGREEMENT or to carry out more
effectively the provisions and purposes hereof, or to better assure and confirm
unto such other PARTY its rights and remedies under this AGREEMENT.

11.13.  

Transaction Costs. Each PARTY shall bear its own costs, including attorneys’
fees, in connection with negotiating and entering into this AGREEMENT.

11.14.  

References. Unless otherwise specified, (a) references in this AGREEMENT to any
Article, Section, Schedule or Exhibit shall mean references to such Article,
Section, Schedule or Exhibit of this AGREEMENT, (b) references in any section to
any clause are references to such clause of such section, (c) references to any
agreement, instrument or other document in this AGREEMENT refer to such
agreement, instrument or other document as originally executed or, if
subsequently varied, replaced or supplemented from time to time, as so varied,
replaced or supplemented and in effect at the relevant time of reference
thereto, and (d) references to Sections include subsections, which are part of
the related Section (e.g., a section numbered “Section 1.1.3” would be part of
“Section 1.1” and references to “Section 1.1” would also refer to material
contained in the subsection described as “Section 1.1.3”).

11.15.  

Construction. Except where the context otherwise requires, wherever used, the
singular shall include the plural, the plural the singular, the use of any
gender shall be applicable to all genders and the word “or” is used in the
inclusive sense (i.e., and/or). The words “hereof,” “herein” and “hereunder” and
words of similar import when used in this AGREEMENT will refer to this AGREEMENT
as a whole and not to any particular provision of this AGREEMENT. Section and
subsection references are to this AGREEMENT, unless otherwise specified. The
captions of this AGREEMENT are for convenience of reference only and in no way
define, describe, extend or limit the scope or intent of this AGREEMENT or the
intent of any provision contained in this AGREEMENT. The term “including” as
used herein shall mean including, without limiting the generality of any
description preceding such term. The language of this AGREEMENT shall be deemed
to be the language mutually chosen by the PARTIES and no rule of strict
construction shall be applied against either PARTY hereto.

**  

This material was omitted pursuant to a request for confidential treatment and
was separately filed with the SEC on March 3, 2008.

[Signature Page Follows]

30

--------------------------------------------------------------------------------

IN WITNESS WHEREOF, the PARTIES hereto have caused this AGREEMENT to be executed
by their duly authorized representatives as of the EXECUTION DATE.

FOR: PALOMAR MEDICAL TECHNOLOGIES, INC. FOR: THE PROCTER & GAMBLE COMPANY    
By: /s/ Joseph P. Caruso          By: /s/ Jeffrey D. Weedman         Name:
Joseph P. Caruso Name: Jeffrey D. Weedman Title: CEO Title: V.P., External
Business Development Date: February 29, 2008 Date: February 29, 2008    

  FOR: THE GILLETTE COMPANY       By: /s/ Jeffrey D. Weedman           Name:
Jeffrey D. Weedman   Title: V.P., External Business Development Date: February
29, 2008

[Counterpart Signature Page to License Agreement]

--------------------------------------------------------------------------------

Exhibit A

APPENDIX OF DEFINITIONS

        This Appendix to the License Agreement between PALOMAR MEDICAL
TECHNOLOGIES, INC. on the one hand, and The PROCTER & GAMBLE COMPANY and THE
GILLETTE COMPANY, on the other hand, entered into as of the last date of
execution of this AGREEMENT and effective retroactively as of February 14, 2003,
provides agreed upon definitions applicable to the PARTIES for purposes of the
AGREEMENT.

DEFINITIONS

1.  

  “ACQUIRING PARTY” is defined in the definition of “CHANGE OF CONTROL”.

2.  

  “AFFILIATE” means, with respect to a PARTY, any corporation, association or
other entity that directly or indirectly controls, is controlled by, or is under
common control with such PARTY, whether through (a) stock ownership, or other
equity interest, direct or indirect or (b) such other arrangement as constitutes
the direct or indirect ability to direct the management, affairs or actions of
such PARTY. As used in the preceding sentence, “control” and “controlled” mean,
with respect to a PERSON, direct or indirect beneficial ownership of more than
fifty percent (50%) of the voting or equity interest in such PERSON; provided,
that if local law restricts foreign ownership, control will be established by
direct or indirect ownership of the maximum ownership percentage that may, under
such local law, be owned by foreign interests. For purposes of this AGREEMENT,
THE GILLETTE COMPANY shall be deemed to be an AFFILIATE of P&G as of the
EFFECTIVE DATE.

3.  

  “AGREEMENT” is defined in the preamble.

4.  

  “BUSINESS DAY” means any day other than Saturday, Sunday, United States
federal holiday, Massachusetts holiday or Ohio holiday. Any other reference in
the AGREEMENT to day or days will include Saturday, Sunday, and each United
States federal holiday, Massachusetts holiday and Ohio holiday.

5.  

**

6.  

**

**  

This material was omitted pursuant to a request for confidential treatment and
was separately filed with the SEC on March 3, 2008.

A-1

--------------------------------------------------------------------------------

7.  

  “CHANGE OF CONTROL” means, with respect to a PERSON, any of the following
transactions with a THIRD PARTY (the “ACQUIRING PARTY”): (a) a merger or
consolidation of such PERSON with the ACQUIRING PARTY which results in the
holders of the voting securities of such PERSON outstanding immediately prior
thereto (other than the ACQUIRING PARTY, its “affiliates” and “associates” (as
such terms are used in the Securities Exchange Act of 1934, as amended)) ceasing
to represent at least fifty percent (50%) of the combined voting power of the
surviving entity (or, if applicable, its parent company) immediately after such
merger or consolidation; (b) the sale to the ACQUIRING PARTY of all or
substantially all of the business of such PERSON to which this AGREEMENT relates
(whether by merger, consolidation, sale of stock, sale of assets or other
similar transaction); or (c) the ACQUIRING PARTY (which shall not be any trustee
or other fiduciary holding securities under an employee benefit plan of such
PERSON, or any corporation owned directly or indirectly by the stockholders of
such PERSON, in substantially the same proportion as their ownership of stock of
such PERSON), together with any of the ACQUIRING PARTY’s “affiliates” or
“associates” ( as such terms are used in the Securities Exchange Act of 1934, as
amended), becoming the beneficial owner of fifty percent (50%) or more of the
combined voting power of the outstanding securities of such PERSON or by
contract or otherwise having the right to control the board of directors or
equivalent governing body of such PERSON or the ability to cause the direction
of management of such PERSON.

8.  

  “CONFIDENTIAL INFORMATION” is defined in Section 5.3.1.

9.  

  “CONSUMER FIELD” means, with respect to products or systems, those intended
for or marketed to consumers for personal use, including through any
DISTRIBUTION CHANNEL(S), provided in each case that any sellers (including any
such retailers and other sellers in any such DISTRIBUTION CHANNELS) do not
permit end-users to use, and are not permitted to have end-users use, such
products in any facilities owned or operated by or on behalf of such retailers
or sellers. For the avoidance of doubt, the “CONSUMER FIELD” shall exclude (a)
products or systems in the PROFESSIONAL FIELD, and (b) products or systems
developed for and sold or distributed to governmental entities for treatment of
medical conditions in military personnel.

10.  

  “CONTROL” means, with respect to any PATENT, KNOW-HOW or other intellectual
property right, or any REGULATORY DOCUMENTATION, possession of the right (other
than as a result of any right or license granted to a PARTY hereunder), whether
directly or indirectly, and whether by ownership, license or otherwise, to
assign, or grant a license, sublicense or other right to or under such PATENT,
KNOW-HOW, other intellectual property right or REGULATORY DOCUMENTATION, without
violating the terms of any agreement or other arrangement with any THIRD PARTY.

11.  

  “CPR” is defined in Section 10.3.1.

12.  

  “CURE PERIOD” is defined in Section 7.2.1.

A-2

--------------------------------------------------------------------------------

13.  

  “CURRENT PRODUCTS” **

14.  

**

15.  

  “DISCLOSABLE INVENTION” is defined in Section 4.2.2.

16.  

  “DISCLOSURE SCHEDULE” is defined in Section 9.1.

17.  

  “DISPUTE” is defined in Section 10.1.

18.  

  “DISPUTE NOTICE” is defined in Section 10.2.

19.  

  “DISTRIBUTION CHANNELS” means, with respect to sales of products or systems,
(a) sales directly to end-users from the selling PARTY’s website, and (b) sales
to retailers and other sellers of product, including drugstores, mass
merchandisers, club stores, dermatologic offices, salons, medi-spas and internet
companies or outlets, as well as non-retail wholesalers and distributors who
will subsequently sell the subject product to any such retailers or sellers.

20.  

  “EFFECTIVE DATE” is defined in the first Paragraph of this AGREEMENT.

21.  

  “EXECUTION DATE” is defined in the first Paragraph of this AGREEMENT.

22.  

  “EXPLOIT” means to make, have made, import, use, sell, or offer for sale,
including to research, develop, register, modify, enhance, improve, manufacture,
have manufactured, formulate, have used, export, transport, distribute, promote,
market or have sold or otherwise dispose of.

23.  

  “EXPLOITATION” means the making, having made, importation, use, sale, offering
for sale or disposition of a product or system, including the research,
development, registration, modification, enhancement, improvement, manufacture,
formulation, optimization, importation, exportation, transportation,
distribution, promotion or marketing of a product or system.

24.  

  “FDA” shall mean the United States Food and Drug Administration and any
successor agency thereto, and any foreign counterpart thereto.

25.  

  “FDCA” means the United States Federal Food Drug and Cosmetic Act, as amended
from time to time, and any foreign counterpart thereto.

26.  

  “FEMALE FIELD” means any product or system, which is intended or marketed for
female HAIR MANAGEMENT through the use of OPTICAL RADIATION in the CONSUMER
FIELD.

27.  

  “FIELD” means any product or system, which is intended or marketed for female
or male HAIR MANAGEMENT through the use of OPTICAL RADIATION in the CONSUMER
FIELD.

**  

This material was omitted pursuant to a request for confidential treatment and
was separately filed with the SEC on March 3, 2008.

A-3

--------------------------------------------------------------------------------

28.  

  “FIRST COMMERCIAL SALE” means the first sale or distribution of any LICENSED
PRODUCT or TTP-BEARING PRODUCT by P&G or any of its sublicensees that gives rise
to NOS under this AGREEMENT **.

29.  

  “FIRST FEMALE PRODUCT” means the LICENSED PRODUCT (a) developed in whole or in
part by PALOMAR or P&G pursuant to the ORIGINAL AGREEMENT, and (b) comprising an
apparatus for delivering OPTICAL RADIATION to areas of the skin, for which
PALOMAR sought and obtained REGULATORY APPROVAL pursuant to PALOMAR’s 510(k)
notification K060839.

30.  

  “FIRST PRESS RELEASE” is defined in Section 5.6.1.

31.  

  “FUNCTIONALITY” shall mean, with respect to a product, process or system, the
operation of such product, process or system, and not the level or degree of
efficacy achieved through use of such product, process or system.

32.  

  “GAAP” means United States generally accepted accounting principles,
consistently applied.

33.  

  “GILLETTE” is defined in the first Paragraph of this AGREEMENT.

34.  

  “GROSS SALES” means the invoiced price of sales of product sold by P&G or any
of its permitted sublicensees to THIRD PARTIES (including distributors,
customers or consumers).

35.  

  “HAIR MANAGEMENT” means (a) the removal of human hair shafts or changes in the
associated structures; or (b) any other reduction of human hair growth, shaft
diameter or pigmentation.

36.  

  “IMPROVEMENT” means any modification, variation or revision to a product,
system or technology or any discovery, technology, device, process or
formulation related to such product, system or technology, whether or not
patented or patentable or otherwise protectable by intellectual property rights,
including any enhancement in the efficiency, operation, manufacture (including
any manufacturing process), ingredients, preparation, presentation, formulation,
means of delivery, powering or operating or packaging of such product, system or
technology, any discovery or development of any new or expanded uses for such
product, system or technology, or any discovery or development that improves the
stability, safety or efficacy of such product, system or technology or reduces
cost of operation or manufacture.

37.  

  “INDEMNIFICATION CLAIM NOTICE”1. is defined in Section 8.3.1.

38.  

  “INDEMNIFIED PARTY” is defined in Section 8.3.1.

39.  

  ** is defined in Section 9.5.1.2.

40.  

  **

**  

This material was omitted pursuant to a request for confidential treatment and
was separately filed with the SEC on March 3, 2008.

A-4

--------------------------------------------------------------------------------

41.  

   “INVENTORSHIP DISPUTE” is defined in Section 10.4.

42.  

  ** is defined in Section 9.5.1.

43.  

  ** is defined in Section 9.5.1.

44.  

  **

45.  

  **

46.  

  **

47.  

 **

48.  

  **

49.  

  **

50.  

  **

51.  

  **

52.  

  “KNOW-HOW” means any unpublished technical and scientific information and
know-how that is not publicly or generally known, but excluding any inventions
to the extent claimed by a PATENT.

53.  

  “LAUNCH” means, with respect to a LICENSED PRODUCT, the date on which the
FIRST COMMERCIAL SALE of such product occurs.

54.  

  “LICENSED KNOW-HOW” means the PALOMAR BACKGROUND KNOW-HOW, PALOMAR INDEPENDENT
KNOW-HOW and PALOMAR PROJECT KNOW-HOW.

55.  

  “LICENSED PATENTS” means the PALOMAR BACKGROUND PATENTS, PALOMAR INDEPENDENT
PATENTS and PALOMAR PROJECT PATENTS.

56.  

  “LICENSED PRODUCT” means any product or system that (a) is within the scope
of, or the making, selling, offering for sale, importing or using of which is
within the scope of, at least one VALID CLAIM of a LICENSED PATENT; or (b) uses
or incorporates or is manufactured using any LICENSED KNOW-HOW.

57.  

  “LICENSED PRODUCT TOPICAL” means any LICENSED PRODUCT consisting of a TOPICAL.

58.  

  “LIGHT-BASED DEVICE” means a product or system to the extent comprising or
consisting of or constituting an apparatus for delivering OPTICAL RADIATION to
areas of the skin. For clarity, a “LIGHT-BASED DEVICE” shall exclude all
TOPICALS.

**  

 This material was omitted pursuant to a request for confidential treatment and
was separately filed with the SEC on March 3, 2008.

A-5

--------------------------------------------------------------------------------

59.  

  “LIGHT-BASED TOPICAL” means any TOPICAL which is intended or marketed for use
with a LIGHT-BASED DEVICE.

60.  

  “LOSSES” is defined in Section 8.1.

61.  

  ** is defined in Section 9.5.1.2.

62.  

  ** is defined in Section 9.5.1.1.

63.  

  “MAJOR MARKET” shall mean each of the United States, Canada, Europe and Japan.

64.  

  **

65.  

  “MGH” means Massachusetts General Hospital.

66.  

  “MGH AGREEMENTS” means (a) that certain License Agreement by and between
PALOMAR and MGH, dated August 18, 1995, (b) that certain Clinical Trial
Agreement by and between PALOMAR and MGH, dated August 18, 1995, and (c) that
certain Joint Patent Agreement by and between PALOMAR and MGH, dated January 1,
2000, in each case as such agreement is amended as of the EFFECTIVE DATE and as
such agreement may be amended or restated thereafter ** in a manner that is not
inconsistent with the terms of this AGREEMENT.

67.  

**

68.  

  “MGH PATENTS” means (a) as of the EFFECTIVE DATE, all PATENTS in existence and
to which PALOMAR has received or is entitled to receive a license from MGH under
the MGH AGREEMENTS, and including the PATENTS listed in Schedule A-68, and (b)
all claims contained in a PATENT that makes a priority claim to any of the
PATENTS that are identified in clause (a) above, provided any such priority
claim has an earliest priority date based solely on the PATENTS that are
identified in clause (a) above.

69.  

**

70.  

  “NET OUTSIDE SALES” and “NOS” mean GROSS SALES to THIRD PARTIES of LICENSED
PRODUCT or TTP-BEARING PRODUCT by P&G and its permitted sublicensees, less **
DISCOUNTS. Any **DISCOUNT which involves a payment by P&G or any of its
sublicensees shall be taken as a deduction against aggregate sales for the
QUARTER in which the expense is accrued by P&G or such sublicensee. For purposes
of determining NOS, LICENSED PRODUCT or TTP-BEARING PRODUCT will be deemed to be
sold when shipped for all sales that are FOB point of shipment and when title
transfers to a THIRD PARTY for all sales that are FOB any location other than
the point of shipment. Sales between or among P&G or its sublicensee(s) will be
excluded from the computation of NOS, but sales by P&G or its sublicensee(s) to
its or their THIRD PARTY customers will be included in the computation of NOS.
Such amounts shall be determined from the books and records of the entity that
invoiced the THIRD PARTY, maintained in accordance with GAAP, or in the case of
non-United States sales, other applicable accounting standards, in each case in
effect from time to time consistently applied. NOS will be translated into USD
on a QUARTERLY basis in accordance with Section 3.11. **

**  

This material was omitted pursuant to a request for confidential treatment and
was separately filed with the SEC on March 3, 2008.

A-6

--------------------------------------------------------------------------------

71.  

  “NEUTRAL” is defined in Section 10.4.3.

72.  

  **

73.  

  “NON-DISCLOSURE AGREEMENT”is defined in Section 5.8.

74.  

  “NON-LIGHT-BASED PRODUCT” shall mean a process, product or system that
achieves one or more of the following effects without the use of OPTICAL
RADIATION generated by such process, product or system: (a) HAIR MANAGEMENT,
(b) the treatment or prevention of cellulite, cosmetic anti-aging skin
applications (including wrinkle reduction, improvement in skin tone, texture and
elasticity, and removal of pigmented and vascular lesions), (c) body
recontouring, (d) the removal, treatment or prevention of warts, subcutaneous
fat, acne, tattoos, scars, birth marks, oily skin, odor, moles and blemishes,
and (e) any other improvement of skin condition, appearance, tone or texture.

75.  

  “NON-PRODUCT COMPONENTS” is defined in Section 3.5.

76.  

  “NON-PROGRAM PRODUCT” is defined in Section 11.2.3.

77.  

  “OPTICAL RADIATION” means optical radiation that is intended to have or has a
therapeutic function or other efficacious effect.

78.  

  “ORIGINAL AGREEMENT” is defined in the preamble to this AGREEMENT.

79.  

  “OWNED PALOMAR PATENT” is defined in Section 9.3.4.

80.  

  “PALOMAR” is defined in the first Paragraph of this AGREEMENT.

81.  

  “PALOMAR BACKGROUND KNOW-HOW” means all KNOW-HOW that PALOMAR CONTROLLED as of
the EFFECTIVE DATE that is necessary or useful for the EXPLOITATION of products
or systems (including LIGHT-BASED DEVICES and LIGHT-BASED TOPICALS) in the
FEMALE FIELD and (b) was disclosed by PALOMAR to P&G as of the EXECUTION DATE.

82.  

  “PALOMAR BACKGROUND PATENTS” means (a) the MGH PATENTS, (b) the PATENTS listed
in Exhibit D under the heading “PALOMAR BACKGROUND PATENTS”, (c) any
substitutions, divisions, continuations, continuations-in-part (to the extent
fully supported by the contents of those listed PATENTS), reissues, renewals,
registrations, confirmations, re-examinations, extensions, supplementary
protection certificates, term extensions (under applicable patent law or other
applicable law), certificates of invention and the like, and any provisional
applications, of any of the foregoing in clause (b) or this clause (c), and (d)
any foreign or international equivalent of any of the foregoing in clause (b) or
clause (c).

83.  

  “PALOMAR BACKGROUND TECHNOLOGY” means the PALOMAR BACKGROUND KNOW-HOW and
PALOMAR BACKGROUND PATENTS.

**  

 This material was omitted pursuant to a request for confidential treatment and
was separately filed with the SEC on March 3, 2008.

A-7

--------------------------------------------------------------------------------

84.  

 **

85.  

 **

86.  

 **

87.  

 **

88.  

 **

89.  

 **

90.  

   “PALOMAR INDEPENDENT KNOW-HOW” means all KNOW-HOW that PALOMAR CONTROLLED
during the term of the ORIGINAL AGREEMENT that is necessary or useful for the
EXPLOITATION of products or systems (including LIGHT-BASED DEVICES and
LIGHT-BASED TOPICALS) in the FEMALE FIELD and (b) was disclosed by PALOMAR to
P&G as of the EXECUTION DATE, other than PALOMAR BACKGROUND KNOW-HOW, PALOMAR
PROJECT KNOW-HOW, or PALOMAR’s right, title and interest in and to JOINT PROJECT
KNOW-HOW.

91.  

   “PALOMAR INDEPENDENT PATENTS” means (a) the PATENTS listed in Exhibit D under
the heading “PALOMAR INDEPENDENT PATENTS”, (b) any substitutions, divisions,
continuations, continuations-in-part (to the extent fully supported by the
contents of those listed PATENTS), reissues, renewals, registrations,
confirmations, re-examinations, extensions, supplementary protection
certificates, term extensions (under applicable patent law or other applicable
law), certificates of invention and the like, and any provisional applications,
of any of the foregoing, and (c) any foreign or international equivalent of any
of the foregoing.

92.  

   “PALOMAR INDEPENDENT TECHNOLOGY”means PALOMAR INDEPENDENT KNOW-HOW and the
PALOMAR INDEPENDENT PATENTS.

93.  

   “PALOMAR MEDICAL TECHNOLOGIES, INC.” is defined in the first Paragraph of
this AGREEMENT.

94.  

   “PALOMAR PROJECT INVENTIONS” means inventions first conceived (as determined
under U.S. patent law) by or on behalf of representatives, employees or agents
of PALOMAR, either alone or jointly (as determined under U.S. patent law) with a
THIRD PARTY research partner of PALOMAR, during the term of the ORIGINAL
AGREEMENT, in each case in connection with activities performed pursuant to, or
arising from, the ORIGINAL AGREEMENT, excluding any JOINT PROJECT INVENTIONS.

95.  

   “PALOMAR PROJECT KNOW-HOW” means all KNOW-HOW first developed by or on behalf
of representatives, employees or agents of PALOMAR, either alone or jointly (as
determined under U.S. patent law) with a THIRD PARTY research partner of
PALOMAR, during the term of the ORIGINAL AGREEMENT, in each case in connection
with activities performed pursuant to, or arising from, the ORIGINAL AGREEMENT,
excluding any JOINT KNOW-HOW.

**  

 This material was omitted pursuant to a request for confidential treatment and
was separately filed with the SEC on March 3, 2008.

A-8

--------------------------------------------------------------------------------

96.  

   “PALOMAR PROJECT PATENTS” means all PATENTS to the extent one or more claims
of such PATENTS claim any PALOMAR PROJECT INVENTIONS, excluding any PALOMAR
BACKGROUND PATENT or PALOMAR INDEPENDENT PATENT.

97.  

   “PALOMAR PROJECT TECHNOLOGY” means the PALOMAR PROJECT INVENTIONS, PALOMAR
PROJECT KNOW-HOW and PALOMAR PROJECT PATENTS.

98.  

   “PALOMAR REGULATORY DOCUMENTATION” means all REGULATORY DOCUMENTATION (a)
developed by PALOMAR pursuant to or in connection with the ORIGINAL AGREEMENT,
or (b) otherwise CONTROLLED by PALOMAR as of the EFFECTIVE DATE or during the
term of the ORIGINAL AGREEMENT applicable to the FEMALE FIELD, including all
documentation and data submitted by PALOMAR to the FDA in connection with, (i)
PALOMAR’s 510(k) notification K060839 and (ii) PALOMAR’s filings under the
electronic product standards provisions of the FDCA and any application or
request by PALOMAR for exemption or variance from the laser performance
standards, including in the case of clause (ii) any initial product reports,
adverse event reports or other supplements thereto, in each case ((a) and (b)),
(x) together with a complete copy of any raw data summarized in any submission
to the FDA covered by clause (a) or (b) above or on which such submission was
based **.

99.  

   “PALOMAR TECHNOLOGY” means the PALOMAR BACKGROUND TECHNOLOGY, PALOMAR
INDEPENDENT TECHNOLOGY and PALOMAR PROJECT TECHNOLOGY.

100.  

   “PARTY” means either PALOMAR or P&G, and “PARTIES” means the two
collectively.

101.  

   “PATENTS” means (a) all national, regional and international patents and
patent applications, including provisional patent applications, (b) any
substitutions, divisions, continuations, continuations-in-part, reissues,
renewals, registrations, confirmations, re-examinations, extensions,
supplementary protection certificates, term extensions (under applicable patent
law or other applicable law), certificates of invention and the like, and any
provisional applications, of any such patents or patent application, and (c) any
foreign or international equivalent of any of the foregoing.

102.  

   **

103.  

   “PERMITTED CONFIDANTS” is defined in Section 5.1.1.

104.  

   “PERSON” means an individual, sole proprietorship, general partnership,
limited partnership, limited liability partnership, corporation, limited
liability company, business trust, joint stock company, trust, unincorporated
association, cooperative, joint venture or other similar entity or organization,
including a government or political subdivision, department or agency of a
government.

**  

 This material was omitted pursuant to a request for confidential treatment and
was separately filed with the SEC on March 3, 2008.

A-9

--------------------------------------------------------------------------------

105.  

   “P&G” is defined in the first Paragraph of this AGREEMENT.

106.  

 **

107.  

 **

108.  

 **

109.  

 **

110.  

 **

111.  

 **

112.  

   “P&G FISCAL YEAR” means the period from July 1 of a given calendar year to
June 30 of the succeeding calendar year.

113.  

   “P&G LICENSED PATENTS” means (a) the P&G PROJECT PATENTS, and (b) those
PATENTS that (i) are CONTROLLED (other than pursuant to this AGREEMENT, and, for
clarity, excluding any JOINT PROJECT PATENTS) by P&G and (ii) claim inventions
that are conceived prior to or during the TERM and are incorporated in LICENSED
PRODUCTS that are developed or under development by P&G prior to or at the time
of termination of this AGREEMENT (including CURRENT PRODUCTS), but only with
respect to such claims and no other claims of such PATENTS **.

114.  

 **

115.  

 **

116.  

 **

117.  

 **

118.  

   “P&G REGULATORY DOCUMENTATION” means all REGULATORY DOCUMENTATION developed
by P&G pursuant to or in connection with the ORIGINAL AGREEMENT, excluding any
PALOMAR REGULATORY DOCUMENTATION and the P&G SELECTED DATA.

119.  

   “PROFESSIONAL FIELD” means, with respect to any products (including
LIGHT-BASED DEVICES and LIGHT-BASED TOPICALS), those intended or marketed for
sale to doctors, health care providers or other commercial service providers for
use on or with patients or customers (and not for resale to any PERSON). For
clarity, the “PROFESSIONAL FIELD” includes, without limitation, consumer
self-use in a facility (e.g., spa, salon, physician’s office or retail outlet)
outside the home.

120.  

   “PROGRAM PRODUCT” is defined in Section 11.2.3.

121.  

 **

**  

 This material was omitted pursuant to a request for confidential treatment and
was separately filed with the SEC on March 3, 2008.

A-10

--------------------------------------------------------------------------------

122.  

 **

123.  

 **

124.  

 **

125.  

   “QUARTER” means each three (3) month period beginning on January 1 and ending
on the next March 31, beginning on April 1 and ending on the next June 30,
beginning on July 1 and ending on the next September 30, or beginning on October
1 and ending on the next December 31; provided, however, that the first QUARTER
for the purposes of this AGREEMENT shall begin on the EFFECTIVE DATE and end on
the earliest of the next March 31, June 30, September 30 or December 31.

126.  

   “REGULATORY APPROVAL” means, on a country-by-country basis, the right with
respect to a product or system to manufacture, sell or distribute such product.
In the case of the United States, sale or distribution of such product may
require, for example, a determination by the FDA of substantial equivalence
following the filing with the FDA of a 510(k) notification, or in the event that
a premarket approval is required, the approval by the FDA of a premarket
approval, and in the case of any other country or territory, any necessary
international or foreign approvals.

127.  

   “REGULATORY AUTHORITY” means any applicable supra-national, federal,
national, regional, state, provincial or local regulatory agencies, departments,
bureaus, commissions, councils or other government entities regulating or
otherwise exercising authority with respect to the EXPLOITATION of products or
systems.

128.  

   “REGULATORY DOCUMENTATION” means all applications, registrations, licenses,
authorizations and approvals (including all regulatory approvals), all
correspondence submitted to or received from REGULATORY AUTHORITIES (including
minutes and official contact reports relating to any communications with any
REGULATORY AUTHORITY) and all supporting documents and all clinical studies and
tests and other safety studies and tests, and all data contained in any of the
foregoing, including all IDEs, 510(k) applications, premarket approval
notifications, marketing authorizations, filings under the electronic product
standards provisions of the FDCA and applications for exemption or variance from
laser standards, INDs, NDAs, advertising and promotion documents, adverse event
files, complaint files and manufacturing records.

129.  

 **

130.  

 **

**  

 This material was omitted pursuant to a request for confidential treatment and
was separately filed with the SEC on March 3, 2008.

A-11

--------------------------------------------------------------------------------

131.  

   “ROYALTY TERM” means, with respect to each LICENSED PRODUCT and each country,
(a) the period commencing on the date of the LAUNCH of such LICENSED PRODUCT in
such country and (b) ending on the date of the last to expire VALID CLAIM of any
LICENSED PATENT in such country that would be infringed by the manufacture, use,
sale, offer for sale or importation of such LICENSED PRODUCT in such country (in
the absence of the license contained in Section 1.1 with respect to any LICENSED
PATENT).

132.  

   “SEC”is defined in Section 5.6.2.

133.  

 **

134.  

 **

135.  

   “SELL-OFF PERIOD” is defined in Section 7.3.5.

136.  

  **

137.  

  “TERM” is defined in Section 7.1.

138.  

 **

139.  

  **

140.  

   “THE PROCTER & GAMBLE COMPANY” is defined in the first Paragraph of this
AGREEMENT.

141.  

   “THIRD PARTY” means any PERSON other than PALOMAR MEDICAL TECHNOLOGIES, INC.
or THE PROCTER & GAMBLE COMPANY or The Gillette Company or any of their
respective AFFILIATES.

142.  

   “THIRD PARTY CLAIM”is defined in Section 8.1.

143.  

   “THIRD PARTY COLLABORATION” shall mean, in the case of either P&G or PALOMAR,
a collaboration or joint venture with a THIRD PARTY with respect to a product,
system or other technology with respect to which such PARTY has material
co-development obligations or co-promotion rights or co-marketing rights.

144.  

 **

145.  

   “TOPICAL” means any topically applied composition, including any lotion, gel,
wax, gas, cream, foam, powder, spray, oil, aerosol, particles or similar
composition.

146.  

   “TRADEMARK” means any word, name, symbol, color, designation or device or any
combination thereof, including any trademark, trade dress, brand mark, trade
name, brand name, logo or business symbol.

**  

 This material was omitted pursuant to a request for confidential treatment and
was separately filed with the SEC on March 3, 2008.

A-12

--------------------------------------------------------------------------------

147.  

   “TTP” means technology transfer payment.

148.  

   “TTP QUARTERLY PAYMENT” is defined in Section 3.3.5.

149.  

   “TTP-BEARING PRODUCT” **

150.  

   “TTP TERM” **

151.  

   “USD” means United States Dollars.

152.  

   “VALID CLAIM” means with respect to a particular country, (a) any claim of an
issued and unexpired PATENT in such country that (i) has not been revoked or
held permanently unenforceable or invalid by a decision of a court or
governmental agency of competent jurisdiction from which no appeal can be taken
or has been taken within the time allowed for appeal in such country, and
(ii) has not been abandoned, disclaimed, denied or admitted to be invalid or
unenforceable through reissue or disclaimer or otherwise in such country; and **

**  

 This material was omitted pursuant to a request for confidential treatment and
was separately filed with the SEC on March 3, 2008.

A-13

--------------------------------------------------------------------------------

Exhibit B

** This material was omitted pursuant to a request for confidential treatment
and was separately filed with the SEC on March 3, 2008.

B-1

--------------------------------------------------------------------------------

Exhibit C

FIRST PRESS RELEASE

NEWS RELEASE for March 3, 2008 at 8:00AM Eastern Time

Kayla Castle Investor Relations Manager Palomar Medical Technologies, Inc.
781-993-2411 ir@palomarmedical.com

PALOMAR AND P&G ENTER NEW LICENSE AGREEMENT

        BURLINGTON, MA (March 3, 2008) … Palomar Medical Technologies, Inc.
(Nasdaq:PMTI), a leading researcher and developer of light-based systems for
cosmetic treatments, today announced that it has entered into a non-exclusive
License Agreement with The Procter & Gamble Company (NYSE:PG) to exploit
home-use light-based hair removal devices for women. This new agreement replaces
the Development and License Agreement entered into by Palomar and The Gillette
Company, (a wholly owned subsidiary of P&G) on February 14, 2003, as Amended and
Restated on February 14, 2007, and as further amended thereafter. Under this new
agreement, P&G retains a non-exclusive license to Palomar’s broad patent
portfolio as well as a non-exclusive license to the extensive technology
developed by Palomar before and during the five year term of the prior
agreement. Prior to launching a commercial product, P&G will pay Palomar $1.25
million per calendar quarter. Following commercial launch P&G will pay Palomar
per product sales under a confidential financial arrangement which addresses
both the patents and technology which are licensed.

        During the term of the prior Development and License Agreement, a
home-use, light-based hair removal device for women was developed by Palomar
together with Gillette. It is the first light-based aesthetic device to receive
a 510(k) over-the-counter (OTC) clearance from the United States Food and Drug
Administration (FDA). OTC clearance allows the product to be marketed and sold
directly to consumers without a prescription. Designed specifically for use in
the home and based on over a decade of research, this consumer device represents
a major breakthrough in the aesthetic device industry.

        In order to achieve FDA clearance, numerous clinical studies with over
600 subjects and thousands of treatments were conducted. These studies
demonstrated that, when used as directed, the light-based device created under
this agreement delivers comfortable, effective, skin-safe hair removal.

        Stephanie Connaughton, Marketing Director, Global Grooming, said: “We
are pleased that we were able to find a win-win outcome that enables continued
work on this promising technology and increases the likelihood of commercial
success.”

        Commenting on this development, Palomar Chief Executive Officer Joseph
P. Caruso said, “We strongly believe that we have developed game changing
technology, and we look forward to seeing P&G’s products on the market. Over the
past five years, Palomar and Gillette worked together to advance the technology
and we have made tremendous progress in moving closer to penetrating the mass
consumer market. Our biggest single achievement together has been penetrating
the regulatory barrier to gain FDA approval of the first laser device for the
home market.”

— more —

--------------------------------------------------------------------------------

Palomar — Page 2

        For more information, please see the non-exclusive License Agreement
filed as Exhibit 10.1 to a Current Report on Form 8-K filed today, the Amended
and Restated Development and License Agreement and Amendment #1 to the Amended
and Restated Development and License Agreement filed as Exhibits 10.1 and 10.2
to a Current Report on Form 8-K filed February 21, 2007 and Amendment #2 to the
Amended and Restated Development and License Agreement filed as Exhibit 10.1 to
a current Report on Form 8-K filed December 21, 2007.

        About Palomar Medical Technologies Inc: Palomar is a leading researcher
and developer of light-based systems for cosmetic treatments. Palomar pioneered
the optical hair removal field, when, in 1997, it introduced the first
high-powered laser hair removal system. Since then, many of the major advances
in light-based hair removal have been based on Palomar technology. In December
2006, Palomar became the first company to receive a 510(k) over-the-counter
(OTC) clearance from the United States Food and Drug Administration (FDA) for a
new, patented, home use, light-based hair removal device. OTC clearance allows
the product to be marketed and sold directly to consumers without a
prescription. There are now millions of light-based cosmetic procedures
performed around the world every year in physician offices, clinics, spas and
salons. Palomar is testing many new and exciting applications to further advance
the hair removal market and other cosmetic applications. Palomar is focused on
developing proprietary light-based technology for introduction to the mass
markets. In addition to the non-exclusive License Agreement with P&G, Palomar
also has an agreement with Johnson & Johnson Consumer Companies to develop and
potentially commercialize home-use, light-based devices for reducing or
reshaping body fat including cellulite, reducing the appearance of skin aging,
and reducing or preventing acne.

        For more information on Palomar and its products, visit Palomar’s
website at www.palomarmedical.com. To continue receiving the most up-to-date
information and latest news on Palomar as it happens, sign up to receive
automatic e-mail alerts by going to the Investor Relations’ section of the
website.

        With the exception of the historical information contained in this
release, the matters described herein contain forward-looking statements,
including but not limited to statements relating to new markets, future royalty
amounts due from third parties, development and introduction of new products,
and financial and operating projections. These forward-looking statements are
neither promises nor guarantees, but involve risk and uncertainties that may
individually or mutually impact the matters herein, and cause actual results,
events and performance to differ materially from such forward-looking
statements. These risk factors include, but are not limited to, results of
future operations, technological difficulties in developing or introducing new
products, the results of future research, lack of product demand and market
acceptance for current and future products, the effect of economic conditions,
challenges in managing joint ventures and research with third parties and
government contracts, the impact of competitive products and pricing,
governmental regulations with respect to medical devices, including whether FDA
clearance will be obtained for future products and additional applications, the
results of litigation, difficulties in collecting royalties, potential
infringement of third-party intellectual property rights, factors affecting the
Company’s future income and resulting ability to utilize its NOLs, and/or other
factors, which are detailed from time to time in the Company’s SEC reports,
including the report on Form 10-K for the year ended December 31, 2006 and the
Company’s quarterly reports on Form 10-Q. Readers are cautioned not to place
undue reliance on these forward-looking statements, which speak only as of the
date hereof. The Company undertakes no obligation to release publicly the result
of any revisions to these forward-looking statements that may be made to reflect
events or circumstances after the date hereof or to reflect the occurrence of
unanticipated events.

###

C-1

--------------------------------------------------------------------------------

Exhibit D

Licensed Patents

**  

This material was omitted pursuant to a request for confidential treatment and
was separately filed with the SEC on March 3, 2008.

D-1

--------------------------------------------------------------------------------

Schedule 2.2.2

**  

**  

This material was omitted pursuant to a request for confidential treatment and
was separately filed with the SEC on March 3, 2008.

--------------------------------------------------------------------------------

Schedule 4.2.2

DISCLOSABLE INVENTIONS

**  

**  

This material was omitted pursuant to a request for confidential treatment and
was separately filed with the SEC on March 3, 2008.

--------------------------------------------------------------------------------

Schedule 9.1

**  

 

 

Palomar Medical Technologies, Inc. v. Lumenis, Ltd., Lumenis, Inc., ESC Medical
Systems, Inc., and ESC/Sharplan Laser Industries Ltd., Trial Court, Superior
Court Dept., Commonwealth of Massachusetts, Civ. Act. No. 02-4565, filed October
29,2002.

 

Lumenis, Inc. v. Palomar Medical Technologies, Inc. and The General Hospital
Corporation, United States District Court, Northern District of California, Civ.
Act. No. 02-5176, filed October 24, 2002.

 

Palomar Medical Technologies, Inc. and The General Hospital Corporation v. Altus
Medical, Inc. v. Palomar Medical Technologies, Inc. and The General Hospital
Corporation, United States District Court, District of Massachusetts, Civ. Act.
No. 02-10258-RWZ.

**  

 

Palomar Medical Technologies, Inc. v. Candela Corporation, Civil Action No:
1:06-cv-11400-RWZ, District of Massachusetts.

**  

**  

This material was omitted pursuant to a request for confidential treatment and
was separately filed with the SEC on March 3, 2008.

--------------------------------------------------------------------------------

Schedule A-68

MGH PATENTS

**  

**  

This material was omitted pursuant to a request for confidential treatment and
was separately filed with the SEC on March 3, 2008.

Schedule A-68 – Page 1

--------------------------------------------------------------------------------